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Abstract
This document provides healthcare practitioners with information regarding the management of acute
rhinosinusitis (ARS) and chronic rhinosinusitis (CRS) to enable them to better meet the needs of this patient
population. These guidelines describe controversies in the management of acute bacterial rhinosinusitis (ABRS) and
include recommendations that take into account changes in the bacteriologic landscape. Recent guidelines in
ABRS have been released by American and European groups as recently as 2007, but these are either limited in
their coverage of the subject of CRS, do not follow an evidence-based strategy, or omit relevant stakeholders in
guidelines development, and do not address the particulars of the Canadian healthcare environment.
Advances in understanding the pathophysiology of CRS, along with the development of appropriate therapeutic
strategies, have improved outcomes for patients with CRS. CRS now affects large numbers of patients globally and
primary care practitioners are confronted by this disease on a daily basis. Although initially considered a chronic
bacterial infection, CRS is now recognized as having multiple distinct components (eg, infection, inflammation),
which have led to changes in therapeutic approaches (eg, increased use of corticosteroids). The role of bacteria in
the persistence of chronic infections, and the roles of surgical and medical management are evolving. Although
evidence is limited, guidance for managing patients with CRS would help practitioners less experienced in this area
offer rational care. It is no longer reasonable to manage CRS as a prolonged version of ARS, but rather, specific
therapeutic strategies adapted to pathogenesis must be developed and diffused.
Guidelines must take into account all available evidence and incorporate these in an unbiased fashion into
management recommendations based on the quality of evidence, therapeutic benefit, and risks incurred. This
document is focused on readability rather than completeness, yet covers relevant information, offers summaries of
areas where considerable evidence exists, and provides recommendations with an assessment of strength of the
evidence base and degree of endorsement by the multidisciplinary expert group preparing the document.
These guidelines have been copublished in both Allergy, Asthma & Clinical Immunology and the Journal of
Otolaryngology-Head and Neck Surgery.
Introduction
Sinusitis refers to inflammation of a sinus, while rhinitis
is inflammation of the nasal mucous membrane. The
proximity between the sinus cavities and the nasal pas-
sages, as well as their common respiratory epithelium,
lead to frequent simultaneous involvement of both
structures (such as with viral infections). Given the diffi-
culty separating the contributions of deep structure to
signs and symptoms, the term rhinosinusitis is fre-
quently used to describe this simultaneous involvement,
and will be used in this text. Rhinosinusitis refers to
inflammation of the nasal cavities and sinuses. When
the inflammation is due to bacterial infection, it is called
bacterial rhinosinusitis.
Rhinosinusitis is a frequently occurring disease, with
significant impact on quality of life and health care
spending, and economic impact in terms of absenteeism
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6 billion dollars is spent in the United States annually
on therapy for rhinosinusitis [1]. A recent study in
Canada described the impact of chronic rhinosinusitis
(CRS) on patients and healthcare utilization [2]. Patients
with CRS had a health status similar to patients with
arthritis, cancer, asthma, and inflammatory bowel dis-
ease. Compared with people without CRS, those with
CRS reported more days spent bedridden and more vis-
its to family physicians, alternative healthcare providers,
and mental health experts. These findings underscore
the significant impact of this disease on patient quality
of life, as well as costs of care to patients and society.
In Canada, 2.89 million prescriptions were dispensed
for acute rhinosinusitis (ARS) or CRS in 2006, with
approximately 2/3 for ARS and 1/3 for CRS [3]. Despite
well-established differences between these 2 diseases in
pathophysiology, bacteriology, and standard specialist
treatment strategies, an assessment of therapies pre-
scribed in Canada for CRS has shown that medications
prescribed for CRS exactly paralleled those prescribed
for ARS [3].
The incidence of bacterial rhinosinusitis is difficult to
obtain precisely given that not all patients will seek medi-
cal help. In the United States in 2007, ARS affected 26
million individuals and was responsible for 12.9 million
office visits [4]. Although no specific Canadian data is
available, extrapolation from US data suggests an occur-
rence of 2.6 million cases in Canada annually. This is in
line with prescription data from 2004. This high inci-
dence is not unexpected given that acute bacterial rhino-
sinusitis (ABRS) usually develops as a complication in
0.5%-2% of upper respiratory tract infections (URTIs) [5].
A survey of Canadian households reported the preva-
lence of CRS to be 5% [6]. The prevalence was higher in
women compared with men (5.7% vs 3.4% for subjects
aged ≥12 years) and increased with age. CRS was asso-
ciated with smoking, lower income, history of allergy,
asthma, or chronic obstructive pulmonary disease
(COPD), and was slightly higher for those living in the
eastern region or among native Canadians.
Guidelines for ARS have been developed over the past
5 years by both a European group (E3POS) and the
American Academy of Otolaryngology-Head and Neck
Surgery (AAO-HNS). Both guidelines have limitations
that we believe are improved upon by the current docu-
ment. This current document provides healthcare prac-
titioners with a brief, easy-to-read review of information
regarding the management of ARS and CRS. These
guidelines are meant to have a practical focus, directed
at first-line practitioners with an emphasis on patient-
centric issues. The readership is considered to be family
physicians, emergency physicians, or other point-of-care
providers, as well as specialists in otolaryngology-head
and neck surgery, allergy and immunology, or infectious
disease who dispense first-line care or teach colleagues
on the subject. This document is specifically adapted for
the needs of the Canadian practice environment and
makes recommendations that take into account factors
such as wait times for computed tomography scans or
specialist referral. These guidelines are intended to pro-
vide useful information for CRS by addressing this area
where controversy is unresolved and evidence is typi-
cally Grade D - requiring incorporation of expert opi-
nion based on pathophysiology and current treatment
regimens. Thus, the main thrust is to provide a compre-
hensive guide to CRS and to address changes in the
management of ABRS.
Guideline Preparation Process
An increased emphasis on evidence-based recommenda-
tions over the past decade has significantly improved
the overall quality of most published guidelines, but pre-
sent significant difficulties in developing guidelines
where the evidence base for long-standing, traditional
remedies is often weak or anecdotal, or in emerging
entities such as chronic rhinosinusitis (CRS) where con-
troversy remains and evidence is sparse. In developing
these guidelines, standard evidence-based development
techniques have been combined with the Delphi voting
process in order to offer the reader the opinion of a
multidisciplinary expert group in areas where evidence
is weak.
Funding was obtained via an unrestricted grant
obtained from 5 pharmaceutical manufacturers, with
each contributing equally to this project. In order to
minimize any appearance of conflict of interest, all
funds were administered via a trust account held at the
Canadian Society of Otolaryngology-Head and Neck
Surgery (CSO-HNS). No contact with industry was
made during the guidelines development or review
process.
An English-language Medline
® search was conducted
using the terms acute bacterial rhinosinusitis (ABRS),
chronic rhinosinusitis (CRS), and nasal polyposis (lim-
ited to the adult population, human, clinical trials, items
with abstracts) and further refined based on the indivi-
dual topics. This is a multi-disciplined condition and
therefore input from all appropriate associations was
required. Inclusion criteria: most current evidence-based
data, relevance, subject specifics, caliber of the abstract,
Canadian data preferred but not exclusive. Exclusion
criteria: newer abstract of the same subject available,
non-human, not relevant.
The quality of retrieved articles was assessed by
Society Team Leaders along with the principal author
based on area of expertise. Where necessary, the princi-
pal author invited input from the External Content
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drawing upon strategies adapted from the American
Academy of Pediatrics Steering Committee on Quality
Improvement and Management (AAP SCQIM) guide-
lines [7], the Grades of Recommendation, Assessment,
Development and Evaluation (GRADE) grading system
[8], and the AAO-HNS guidelines in sinusitis [9], all of
which use similar strategies by classifying strength of
evidence recommendations according to the balance of
the benefits and downsides after considering the quality
of the evidence. Accordingly, grades of evidence were
defined as:
Grade A. Well-designed, randomized, controlled stu-
dies or diagnostic studies on relevant populations
Grade B. Randomized controlled trials or diagnostic
studies with minor limitations; overwhelmingly con-
sistent evidence from observational studies
Grade C. Observational studies (case control or
cohort design)
Grade D. Expert opinion, case reports, reasoning
from first principles
Grade X. Exceptional situations where validating stu-
dies cannot be done and there is a clear predomi-
nance of benefit or harm [7].
Strength of Evidence
Definitions for the strength of evidence recommenda-
tions combine the balance of benefit versus harm of
treatment with the grade of the evidence, as follows:
Strong Recommendation: Benefits of treatment
clearly exceed harm; quality of evidence is excellent
(Grade A or B). A strong recommendation should
be followed unless there is a clear and compelling
reason for a different approach.
Recommendation: Benefits exceeded harm, but qual-
ity of evidence is not as strong (Grade B or C). A
recommendation should generally be followed, but
clinicians should remain alert to new information
and consider patient preferences.
Option: Quality of evidence is suspect (Grade D) or
well-done studies (Grade A, B or C) show little clear
advantage. An option reflects flexibility in decision-
making regarding appropriate practice, but clinicians
may set limits on alternatives. The preference of the
patient should influence the decision.
No Recommendation: A lack of relevant evidence
(Grade D) and an unclear balance between benefits
and harm. No recommendation reflects no limita-
tions on decision-making and clinicians should be
vigilant regarding new information on the balance of
benefit versus harm. The preference of the patient
should influence the decision.
I ns i t u a t i o n sw h e r eh i g h - q u a l i t ye v i d e n c ei si m p o s s i b l et o
obtain and anticipated benefits strongly outweigh the harm,
the recommendation may be based on lesser evidence [9].
Thus, policy recommendations were formulated based
on evidence quality and the balance of potential benefits
and harm. As many therapies have not been subjected
to safety evaluation in a clinical trial setting, the poten-
tial for harm was assessed for each therapy and weighs
in the recommendation. The guidelines presented used
these approaches to formulate strength of evidence
recommendations, with options to recommend denoted
as:
￿ Strong
￿ Moderate
￿ Weak
￿ An option for therapy, or
￿ Not recommended as either clinical trial data of a
given therapy did not support its use or a concern
for toxicity was noted.
Strength of Recommendation
Recommendations were assessed according to a Delphi
voting process, whereby voting options included to
accept completely, to accept with some reservation, to
accept with major reservation, to reject with reservation,
or to reject completely [7,10]. Only statements that were
accepted by over 50% of the group were retained.
Strength of the recommendation by the multidisciplin-
ary group of experts was denoted as:
￿ Strong (for accept completely)
￿ Moderate (for accept with some reservation), or
￿ Weak (for accept with major reservation).
Thus, strength of recommendation is a measure of
endorsement by the group of experts.
These guidelines have been developed from the outset
to meet the AGREE criteria [11] to ensure maximum
impact.
DISCLAIMER: These guidelines are designed to offer
evidence-based strategies in the management of acute
and chronic rhinosinusitis. They are, however, not
intended to replace clinical judgment or establish a pro-
tocol for all individuals with suspected rhinosinusitis. Dif-
ferent presentations, associated comorbidities, or
availability of resources may require adaptation of these
guidelines, thus there may be other appropriate
approaches to diagnosing and managing these conditions.
Summary of Guideline Statements and Strengths
Statements and their ratings for strength of evidence
and recommendation are summarized in Table 1.
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Page 3 of 38Table 1 Guideline Statements and Strengths for Acute Bacterial Rhinosinusitis and Chronic Rhinosinusitis
Statement Strength of
Evidence*
Strength of
Recommendation
†
Acute Bacterial Rhinosinusitis
1: ABRS may be diagnosed on clinical grounds using symptoms and signs of more than 7 days
duration.
Moderate Strong
2. Determination of symptom severity is useful for the management of acute sinusitis, and can be
based upon the intensity and duration and impact on patient’s quality of life.
Option Strong
3: Radiological imaging is not required for the diagnosis of uncomplicated ABRS. When performed,
radiological imaging must always be interpreted in light of clinical findings as radiographic images
cannot differentiate other infections from bacterial infection and changes in radiographic images can
occur in viral URTIs.
Moderate Strong
Criteria for diagnosis of ABRS are presence of an air/fluid level or complete opacification. Mucosal
thickening alone is not considered diagnostic. Three-view plain sinus X-rays remain the standard.
Computed tomography (CT) scanning is mainly used to assess potential complications or where regular
sinus X-rays are no longer available.
Radiology should be considered to confirm a diagnosis of ARBS in patients with multiple recurrent
episodes, or to eliminate other causes.
4: Urgent consultation should be obtained for acute sinusitis with unusually severe symptoms or
systemic toxicity or where orbital or intracranial involvement is suspected.
Option Strong
5: Routine nasal culture is not recommended for the diagnosis of ABRS. When culture is required for
unusual evolution, or when complication requires it, sampling must be performed either by maxillary tap
or endoscopically-guided culture.
Moderate Strong
6: The 2 main causative infectious bacteria implicated in ABRS are Streptococcus pneumoniae and
Haemophilus influenzae.
Strong Strong
7: Antibiotics may be prescribed for ABRS to improve rates of resolution at 14 days and should be
considered where either quality of life or productivity present as issues, or in individuals with severe
sinusitis or comorbidities. In individuals with mild or moderate symptoms of ABRS, if quality of life is not
an issue and neither severity criterion nor comorbidities exist, antibiotic therapy can be withheld.
Moderate Moderate
8: When antibiotic therapy is selected, amoxicillin is the first-line recommendation in treatment of
ABRS. In beta-lactam allergic patients, trimethoprim-sulfamethoxazole (TMP/SMX) combinations or a
macrolide antibiotic may be substituted.
Option Strong
9: Second-line therapy using amoxicillin/clavulanic acid combinations or quinolones with enhanced
gram positive activity should be used in patients where risk of bacterial resistance is high, or where
consequences of failure of therapy are greatest, as well as in those not responding to first-line therapy. A
careful history to assess likelihood of resistance should be obtained, and should include exposure to
antibiotics in the prior 3 months, exposure to daycare, and chronic symptoms.
Option Strong
10: Bacterial resistance should be considered when selecting therapy. Strong Strong
11: When antibiotics are prescribed, duration of treatment should be 5 to 10 days as recommended by
product monographs. Ultra-short treatment durations are not currently recommended by this group.
Strong Moderate
12: Topical intranasal corticosteroids (INCS) can be useful as sole therapy of mild-to-moderate ARS. Moderate Strong
13: Treatment failure should be considered when patients fail to respond to initial therapy within 72
hours of administration. If failure occurs following use of INCS as monotherapy, antibacterial therapy
should be administered. If failure occurs following antibiotic administration, it may be due to lack of
sensitivity to, or bacterial resistance to, the antibiotic, and the antibiotic class should be changed.
Option Strong
14: Adjunct therapy should be prescribed in individuals with ABRS. Option Strong
15. Topical INCS may help improve resolution rates and improve symptoms when prescribed with an
antibiotic.
Moderate Strong
16. Analgesics (acetaminophen or non-steriodal anti-inflammatory agents) may provide symptom relief. Moderate Strong
17. Oral decongestants may provide symptom relief. Option Moderate
18. Topical decongestants may provide symptom relief. Option Moderate
19. Saline irrigation may provide symptom relief. Option Strong
20. For those not responding to a second course of therapy, chronicity should be considered and the
patient referred to a specialist. If waiting time for specialty referral or CT exceeds 6 weeks, CT should be
ordered and empiric therapy for CRS administered. Repeated bouts of acute uncomplicated sinusitis
clearing between episodes require only investigation and referral, with a possible trial of INCS. Persistent
symptoms of greater than mild-to-moderate symptom severity should prompt urgent referral.
Option Moderate
21: By reducing transmission of respiratory viruses, hand washing can reduce the incidence of viral and
bacterial sinusitis. Vaccines and prophylactic antibiotic therapy are of no benefit.
Moderate Strong
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Definition and Diagnosis
Statement 1: ABRS may be diagnosed on clinical grounds
using symptoms and signs of more than 7 days duration.
Strength of evidence: Moderate
Strength of recommendation: Strong
Rationale: ABRS is a clinical diagnosis that must be
differentiated from uncomplicated viral infections of the
upper respiratory passages. Although no single symptom
accurately predicts the presence or absence of bacterial
infection, the presence of several signs and symptoms
increases the predictive value.
Definition
The common cold is caused by a rhinovirus, and in most
cases peak symptom severity is reached by 3 days [12].
However, the same virus can activate an inflammatory
process that can lead to bronchitis, pharyngitis, and rhino-
sinusitis [13]. Thus, the term rhinosinusitis has been used
to distinguish this more severe phenotypic entity from the
common cold, which is associated with sinusitis [14].
Despite the frequency of the common cold, 0.5% to 2% of
individuals with the common cold will develop ABRS [5].
ABRS is defined as a bacterial infection of the parana-
sal sinuses, described as a sudden onset of symptomatic
Table 1 Guideline Statements and Strengths for Acute Bacterial Rhinosinusitis and Chronic Rhinosinusitis (Continued)
22: Allergy testing or in-depth assessment of immune function is not required for isolated episodes but
may be of benefit in identifying contributing factors in individuals with recurrent episodes or chronic
symptoms of rhinosinusitis.
Moderate Strong
Chronic Rhinosinusitis
23: CRS is diagnosed on clinical grounds but must be confirmed with at least 1 objective finding on
endoscopy or computed tomography (CT) scan.
Weak Strong
24: Visual rhinoscopy assessments are useful in discerning clinical signs and symptoms of CRS. Moderate Moderate
25: In the few situations when deemed necessary, bacterial cultures in CRS should be performed either
via endoscopic culture of the middle meatus or maxillary tap but not by simple nasal swab.
Option Strong
26: The preferred means of radiological imaging of the sinuses in CRS is the CT scan, preferably in the
coronal view. Imaging should always be interpreted in the context of clinical symptomatology because
there is a high false-positive rate.
Moderate Strong
27: CRS is an inflammatory disease of unclear origin where bacterial colonization may contribute to
pathogenesis. The relative roles of initiating events, environmental factors, and host susceptibility factors
are all currently unknown.
Weak Moderate
28: Bacteriology of CRS is different from that of ABRS. Moderate Strong
29: Environmental and physiologic factors can predispose to development or recurrence of chronic
sinus disease. Gastroesophageal reflux disease (GERD) has not been shown to play a role in adults.
Moderate Strong
30: When diagnosis of CRS is suggested by history and objective findings, oral or topical steroids with
or without antibiotics should be used for management.
Moderate Moderate
31: Many adjunct therapies commonly used in CRS have limited evidence to support their use. Saline
irrigation is an approach that has consistent evidence of benefiting symptoms of CRS.
Moderate Moderate
32. Use of mucolytics is an approach that may benefit symptoms of CRS. Option Moderate
33. Use of antihistamines is an approach that may benefit symptoms of CRS. Option Weak
34. Use of decongestants is an approach that may benefit symptoms of CRS. Option Weak
35. Use of leukotriene modifiers is an approach that may benefit symptoms of CRS. Weak Weak
36: Failure of response should lead to consideration of other possible contributing diagnoses such as
migraine or temporomandibular joint dysfunction (TMD).
Option Moderate
37: Surgery is beneficial and indicated for individuals failing medical treatment. Weak Moderate
38: Continued use of medical therapy post-surgery is key to success and is required for all patients.
Evidence remains limited.
Moderate Moderate
39 Part A: Patients should be referred by their primary care physician when failing 1 or more courses of
maximal medical therapy or for more than 3 sinus infections per year.
Weak Moderate
39 Part B: Urgent consultation with the otolaryngologist should be obtained for individuals with
severe symptoms of pain or swelling of the sinus areas or in immunosuppressed patients.
Weak Strong
40: Allergy testing is recommended for individuals with CRS as potential allergens may be in their
environment.
Option Moderate
41: Assessment of immune function is not required in uncomplicated cases. Weak Strong
42: Prevention measures should be discussed with patients. Weak Strong
*Strength of evidence integrates the grade of evidence with the potential for benefit and harm.
†Strength of recommendation indicates the level of endorsement of the statement by the panel of experts.
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4 weeks. Within this 4-week period, symptoms resolve
either spontaneously or with appropriate treatment
[15,16]. There may be up to 3 episodes per year and full
recovery in between episodes. ABRS commonly occurs
as a complication of a viral upper respiratory tract infec-
tion (URTI) [16,17] and is therefore difficult to differ-
entiate from a viral infection. Recurrent ABRS is defined
as 4 or more episodes of ABRS per year. Symptoms of
ABRS have been classified as major and minor (Table 2)
[18]. Although minor symptoms may be clinically help-
ful, they are not used for the diagnosis of ABRS.
Diagnosis
Although sinus aspirates are considered to be the gold
standard for diagnosis, this invasive procedure is not
recommended in a primary care setting [15]. Clinicians
thus must rely on history and physical examination for
the initial evaluation of ABRS. ABRS can be diagnosed
based on the presence of persistent or worsening symp-
toms (Table 3) [9,19-21]. An algorithm for the diagnosis
and treatment of ABRS is presented in Figure 1.
In sinus aspirate studies, symptoms lasting longer than
10 days were more likely due to ABRS [23]. The 7-to-
10-day specification is based on the natural history of
rhinovirus infections [22]. The presence of several signs
and symptoms increases the predictive value.
Several consensus-based diagnostic criterion have been
developed to aid clinicians in the diagnosis. The Centers
for Disease Control and Prevention recommends reser-
ving the diagnosis of ABRS for patients with:
￿ Symptoms lasting at least 7 days and
￿ Purulent nasal secretions and
￿ 1 of the following:
○ Maxillary pain
○ Tenderness in the face (especially unilateral)
○ Tenderness of the teeth (especially unilateral)
[20].
Two studies of patients presenting with symptoms of
sinusitis have led to the development of prediction
rules. In 1 study, Berg et al reported that 2 or more
positive findings provided 95% sensitivity and 77% speci-
ficity for sinusitis (Table 4) [24]. In the second study,
Williams et al identified 5 independent predictors of
sinusitis that were consistent with radiographic findings
(Table 5) [25].
Prediction rules can be used to aid in diagnosis. Using
either the Berg or Williams prediction rules, the prob-
ability of ABRS increases with cumulative symptoms
[24,25]. Although none of these symptoms are individu-
ally sensitive or specific for diagnosis, the reported num-
ber of diagnostic factors is felt to correlate well with the
likelihood of bacterial infection [26].
A Canadian Medical Association evidence-based
review recommended a score based on Williams’ 5 inde-
pendent predictor symptoms [27]. Fewer than 2 symp-
toms ruled out ABRS (positive predictive value [PPV], <
40%), 4 or more symptoms ruled in ABRS (PPV, 81%),
and 2 or 3 symptoms (PPV, 40%-63%) suggested that
radiography might be beneficial to clarify the diagnosis.
More recent studies have emphasized limitations of clin-
ical findings alone and have either introduced new diag-
nostic elements or else assessed the accuracy of existing
symptoms. In a study of 50 patients with upper respiratory
tract symptoms of at least 1 week and self-suspected acute
maxillary sinusitis, no distinct clinical signs or symptoms
were identified that increased diagnostic accuracy [28].
The sensitivity and specificity of the usual clinical signs
and symptoms ranged from 0.04 to 0.74 in a small pro-
spective study that defined acute sinusitis (not necessarily
bacterial) as 1 or more sinuses with an air fluid level or
complete opacification [29]. A history of facial pain and
sinus tenderness on percussion were inversely associated
with sinusitis (likelihood ratio [LR] < 1.0). Positive LRs
were 1.89 (95% confidence interval [CI], 1.06 to 3.39) for
symptom duration longer than 10 days, 1.47 (CI, 0.93 to
2.32) for purulent nasal secretions on history, 2.11 (CI,
1.23 to 3.63) for oropharyngeal red streak in the lateral
pharyngeal recess, 1.89 (CI, 1.08 to 3.32) for transillumina-
tion, and 1.22 (CI, 0.08 to 18.64) for otitis media.
Although transillumination is not considered accurate in
the diagnosis of acute rhinosinusitis (ARS),[16] visualiza-
tion of purulent secretions from the middle meatus using
Table 2 Symptoms of ABRS
Major Minor
Facial pain/pressure/fullness Headache
Nasal obstruction Halitosis
Nasal purulence/discolored postnasal discharge Fatigue
Hyposmia/anosmia Dental pain
Cough
Ear pain/pressure
Table 3 ABRS Diagnosis Requires the Presence of at Least
2 Major Symptoms*
Major Symptom
P Facial Pain/pressure/fullness
O Nasal Obstruction
D Nasal purulence/discolored postnasal Discharge
S Hyposmia/anosmia (Smell)
*At least 1 symptom must be nasal obstruction or nasal purulence/discolored
postnasal discharge. Thus, a diagnosis requires at least 2 PODS, one of which
must be O or D.
Consider ABRS when viral URTI persists beyond 10 days or worsens after 5 to
7 days with similar symptoms [22]. Bacterial etiology should be suspected if
sinus symptoms persist for more than 7 days without improvement [20].
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dictive of ARS [25]. Young et al suggested that purulent
nasal discharge, signs of pus in the nasal cavity, or sore
throat are better criteria than radiography for selecting
patients who would benefit from antibiotic therapy [30].
Taken together, these results emphasize the diffi-
culty of making an accurate diagnosis of sinusitis but
support existing consensus that symptoms with dura-
tion-based criteria are the best currently available
tool.
Figure 1 Algorithm for the Diagnosis and Treatment of ABRS.
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Statement 2: Determination of symptom severity is use-
ful for the management of acute sinusitis, and can be
based upon the intensity and duration and impact on
patient’s quality of life.
Strength of evidence: Option
Strength of recommendation: Strong
Rationale: Although most of the emphasis of diagno-
sis has been placed upon differentiating between viral
and bacterial causes of sinusitis, or when bacterial sinu-
sitis is diagnosed, little attention has been devoted to
determining the severity of symptomatology as mea-
sured by its impact on the patient’s quality of life. While
guidelines for determining severity of sinusitis have not
been extensively studied [19], it is clear that a need for
this exists. These guidelines recommend determining
the severity of sinusitis, whether viral or bacterial, based
upon the intensity and duration of symptoms and their
impact on the patient’s quality of life.
Symptom severity can be generally categorized as:
￿ Mild: occasional limited episode
￿ Moderate: steady symptoms but easily tolerated
￿ Severe: hard to tolerate and may interfere with
activity or sleep.
Radiological Imaging
Statement 3: Radiological imaging is not required for the
diagnosis of uncomplicated ABRS. When performed,
radiological imaging must always be interpreted in light
of clinical findings, as radiographic images cannot differ-
entiate other infections from bacterial infection and
changes in radiographic images can occur in viral URTIs.
Criteria for diagnosis of ABRS are presence of an air/
fluid level or complete opacification. Mucosal thickening
alone is not considered diagnostic. Three-view plain
sinus X-rays remain the standard. Computed tomogra-
phy (CT) scanning is mainly used to assess potential
complications or where regular sinus X-rays are no
longer available.
Radiology should be considered to confirm a diagnosis
of ARBS in patients with multiple recurrent episodes, or
to eliminate other causes.
Strength of evidence: Moderate
Strength of recommendation: Strong
Rationale: Studies demonstrate that abnormal
images of the sinuses cannot stand alone as diagnostic
evidence of bacterial rhinosinusitis. Radiologic changes
such as simple mucosal thickening are present in most
cases of acute viral infections of the upper respiratory
tract when sensitive detection methods such as CT
scan are used. Incidental findings of mucosal thicken-
ing can also be seen in a high percentage of asympto-
matic individuals.
In 1994, Gwaltney et al found that abnormalities of
the paranasal sinuses on CT scan are extremely com-
mon in young adults with acute uncomplicated viral
URTIs [14]. Another study reported that abnormalities
on CT scans were common even among the general
population [31]. Furthermore, radiographic findings of
inflammation demonstrating chronic rhinosinusitis
(CRS) are found in 27% to 42% of asymptomatic indivi-
duals [32,33]. Taken together, these studies highlight the
need to correlate clinical presentation with radiographic
results when imaging is used to diagnose ABRS.
Statement 4: Urgent consultation should be obtained
for acute sinusitis with unusually severe symptoms or
systemic toxicity or where orbital or intracranial involve-
ment is suspected.
Strength of evidence: Option
Strength of recommendation: Strong
Rationale: Extension of disease beyond the confines of
the sinuses is a medical emergency and requires aggres-
sive assessment, medical therapy, and potential surgical
drainage. Individuals with suspected complications
should be urgently referred to a setting with appropriate
imaging facilities and qualified specialty care.
Table 4 Berg Prediction Rule Based on Signs and Symptoms of ABRS [24]
Sign or Symptom Positive Predictive Value (PPV), %
Purulent rhinorrhea with unilateral predominance 50
Local pain with unilateral predominance 41
Pus in nasal cavity 17
Bilateral purulent rhinorrhea 15
Presence of ≥3 symptoms has a positive likelihood ratio (LR) of 6.75.
Table 5 Williams Prediction Rule Based on Signs and
Symptoms of ABRS [25]
Sign or Symptom Likelihood Ratio (LR)
(present)
Maxillary toothache 2.5
Poor response to antihistamines/
decongestants
2.1
Purulent nasal secretions 2.1
Abnormal transillumination 1.6
Colored nasal discharge 1.5
Presence of ≥4 symptoms has a positive LR of 6.4.
Desrosiers et al. Allergy, Asthma & Clinical Immunology 2011, 7:2
http://www.aacijournal.com/content/7/1/2
Page 8 of 38Red flags for urgent referral include:
￿ Systemic toxicity
￿ Altered mental status
￿ Severe headache
￿ Swelling of the orbit or change in visual acuity.
Orbital and intracranial complications are the most
feared complications of both acute and chronic rhinosi-
nusitis. In the pre-antibiotic era, 20% of patients with
orbital cellulitis went blind and 17% of patients died
from intracranial sepsis [34]. Even in the current era,
complications can result in permanent blindness or
death if not treated appropriately and aggressively.
Visual loss from sinusitis was reported at a rate of up to
10% in a 1991 study [35].
Periorbital or orbital cellulitis is the most common
complication of ABRS and most often caused by acute
ethmoid and/or frontal disease [36,37]. Infection spreads
from the sinuses to the orbit with relative ease [38,39].
Periorbital cellulitis is seen on CT as soft tissue swelling
and manifests as orbital pain, edema, and high fever. If
not aggressively treated, it may spread beyond the orbi-
tal septum. Postseptal inflammation involves structures
of the orbit with the development of proptosis, limita-
tion of ocular motion, pain and tenderness, and con-
junctival chemosis. A subperiosteal or orbital abscess
may result in ophthalmoplegia (globe becomes fixed as a
result of extra-ocular muscle paralysis) and diminished
visual acuity. A CT scan showing evidence of an abscess,
or lack of clinical improvement after 24 to 48 hrs of
intravenous antibiotics are indications for surgical
exploration and drainage. Blindness may result from
central retinal artery occlusion, optic neuritis, corneal
ulceration, or pan-ophthalmitis.
Altered mental status and non-specific signs charac-
terized by high fever, frontal or retro-orbital migraine,
and the presence of generic signs of meningeal irritation
warrant immediate consultation with an Ear Nose
Throat (ENT) specialist and CT scanning (with con-
trast). Infection can spread from the sinuses to the
intracranial structures [40]. Intracranial complications
can include osteomyelitis of the frontal bone (Pott’s
puffy tumor), meningitis, subdural empyema, epidural
abscess, brain abscess, and cavernous sinus thrombosis.
The mortality rate for intracranial complications ranges
from 20% to 60% [41]. High-dose, long-term intravenous
antibiotic therapy followed by endoscopic drainage or
craniotomy and surgical drainage are usually required
for successful treatment [42].
Because of the serious nature of complications,
patients with suspected complications of ABRS should
be immediately referred to an otolaryngologist with
appropriate consultation from other services, including
(but not limited to) ophthalmology, neurosurgery, and
infectious diseases.
Microbiology of ABRS
Statement 5: Routine nasal culture is not recommended
for the diagnosis of ABRS. When culture is required for
unusual evolution, or when complication requires it,
sampling must be performed either by maxillary tap or
endoscopically-guided culture.
Strength of evidence: Moderate
Strength of recommendation: Strong
Rationale: Sinus puncture and aspiration remain the gold
standard for determining the etiology of ABRS. However
because of the invasive nature of sinus puncture required
for bacterial studies, this procedure is rarely performed.
The bacterial etiology of ABRS has been well defined
by numerous studies dating back almost 50 years. Typi-
cally, the findings between investigators have been con-
cordant [5,43-46]:
￿ Sinus puncture and aspiration remain the gold
standard for determining the etiology of ABRS, but
are rarely performed due to the invasive nature of
sinus puncture
￿ Cultures obtained from the nasal passages do not
provide any diagnostic value
￿ ABRS can be differentiated from viral etiology by a
sinus aspirate that shows the presence of >10
4 col-
ony forming units of bacteria/mL or if polymorph
nuclear cells in sinus fluid exceeds 5000 cells/mL
￿ Lower quantities of bacteria may represent early
stages of infection.
Comparisons of endoscopically-directed middle meatus
cultures (EDMM), a less invasive approach to bacterial
sampling, with maxillary sinus aspirate (MSA; the gold
standard) have reported similar results [47-49]. A meta-
analysis comparing the sensitivity and specificity of
EDMM with MSA for ABRS reported that EDMM had a
sensitivity of 81%, specificity of 91%, and overall accuracy
of 87% compared with MSA [50]. Study authors con-
cluded that EDMM was a reliable alterative to MSA for
obtaining cultures from patients with suspected ABRS.
Take Home Points
ABRS is a bacterial infection of the paranasal sinuses
characterized by:
￿ Sudden onset of symptomatic sinus
infection
￿ Symptom duration > 7 days
￿ Length of episode < 4 weeks.
Major symptoms (PODS):
￿ Facial Pain/pressure/fullness
￿ Nasal Obstruction
￿ Nasal purulence/discolored postnasal
Discharge
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Diagnosis requires the presence of ≥ 2 PODS, one of
which must be O or D, and symptom duration of >
7 days without improvement.
Diagnosis is based on history and physical
examination:
￿ Sinus aspirates or routine nasal culture are
not recommended
￿ Radiological imaging is not required for
uncomplicated ABRS.
The severity of sinusitis, whether viral or bacterial,
should be based upon the intensity and duration of
symptoms and their impact on the patient’sq u a l i t y
of life.
Because complications of ABRS can elicit a medical
emergency, individuals with suspected complications
should be urgently referred for specialist care.
Red flags for urgent referral include:
￿ Systemic toxicity
￿ Altered mental status
￿ Severe headache
￿ Swelling of the orbit or change in visual
acuity.
Bacteriology
Statement 6: The 2 main causative infectious bacteria
implicated in ABRS are Streptococcus pneumoniae and
Haemophilus influenzae.
Strength of evidence: Strong
Strength of recommendation: Strong
Rationale: The bacteriology of ABRS in adults has
been well documented in multiple clinical trials and
mainly involves Sp n e u m o n i a eand Hi n f l u e n z a e ,w i t ha
small percentage of other agents such as Moraxella cat-
arhallis and Staphylococcus aureus.T h ec a u s a t i v er o l e
of these less common pathogens has not been well
established.
Streptococcus pneumoniae and Haemophilus influenzae
In virtually every study, S pneumoniae and H influenzae
remain the 2 most predominant pathogens cultured
from the maxillary sinus, typically accounting for more
than 50% of cases [5,43-46]. Between 1975 and 1989,
Gwaltney et al demonstrated that the most common
pathogens in patients with ABRS were Sp n e u m o n i a e
(41%) and H influenzae (35%) [44]. Several years later,
the same author compiled data from 8 additional studies
and again S pneumoniae and H influenzae remained the
most frequent pathogens isolated from diseased maxil-
lary sinuses [5]. More recent data has borne out the
results of historical studies [51,52]. Although limited
data exist, cultures obtained from other sinus cavities
appear to correlate with findings obtained from the
maxillary sinus [53]. H influenzae and S pneumoniae are
most often isolated in pure culture but are occasionally
found together or in combination with other organisms
[45,46,52,54]. H influenzae strains isolated from sinus
puncture are almost exclusively unencapsulated (non-
typeable).
Other Pathogens
M catarrhalis is infrequently isolated from the adult
population, but is more common in children where it
accounts for approximately 25% of bacteria [55]. Other
organisms commonly isolated include S pyogenes, S aur-
eus, gram-negative bacilli, and the oral anaerobes
[5,51,52].
An exception appears to be acute sinusitis of odonto-
genic origin, where anaerobic organisms appear to pre-
dominate. In 1 study, anaerobes were recovered in 50%
of patients, and predominately consisted of Peptostrepto-
coccus spp, Fusobacterium spp, and Prevotella spp [53].
Mixed anaerobic and facultative anaerobic bacteria were
recovered in an additional 40% of patients, including the
alpha-haemolytic Streptococci, microaerophilic Strepto-
cocci,a n dSa u r e u s . Only 5% of odontogenic specimens
grew either Sp n e u m o n i a eor H influenzae. Beta-lacta-
mase producing bacteria were isolated from 10 of 20
specimens.
Severity of Disease Linked to Pathogen
Several recent studies have increased our understanding
of the bacterial etiology associated with ABRS. At least
1 study has demonstrated that severity of disease is
dependent on the infecting pathogen [56]. Compared
with patients infected with H influenzae,p a t i e n t s
infected with Sp n e u m o n i a eshowed a significantly
higher incidence of severe disease (39.2% vs 23.6%, P =
.0097) and complete sinus opacification (46.2% vs 29.2%,
P = .0085). Another study has suggested that although S
pneumoniae and H influenzae remain the predominant
pathogens, the relative frequency between them may
have been altered in adults by the use of the 7-valent
pneumococcal vaccine in children [57]. In the 4 years
prior to the introduction of the vaccine, isolates
obtained from the maxillary sinus of 156 adults predo-
minately grew S pneumoniae (46%), followed by H influ-
enzae (36%). After introduction of the vaccine, the most
predominant organisms recovered from 229 adults were
Hi n f l u e n z a e(43%) and then Sp n e u m o n i a e(35%). The
difference noted in the rate of recovery of H influenzae
and S pneumoniae between the 2 time frames was statis-
tically significant (P < .05).
The Rise of Resistant Bacteria
Recent reviews of antimicrobial resistance trends high-
light the increasing rates of penicillin, macrolide, and
multi-drug resistant Sp n e u m o n i a ein community-
acquired respiratory tract infections. Ongoing cross-
Canada surveillance has reported increased non-suscept-
ibility and resistance since 1988 (Figure 2) [58,59]. In
2007, the prevalence of penicillin non-susceptibility in
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lin remains active against Sp n e u m o n i a e ,w i t ht h er a t e
of resistance remaining under 2% [57,61]. Also, despite
the increasing use of levofloxacin, moxifloxacin and gati-
floxacin, resistance to ciprofloxacin has remained stable
[58]. It should be noted that resistance to erythromycin
implies cross-resistance to the newer macrolides, clari-
thromycin and azithromycin. Resistance to the newer
fluoroquinolones (levofloxacin and moxifloxacin)
remains very low (< 2%) [58].
Higher levels of beta-lactamase production in Hi n f l u -
enzae and M catarrhalis have been reported [62]. Also,
since the introduction of the 7-valent pneumococcal
vaccine in children, there has been a shift in the causa-
tive agent of adult community acute maxillary sinusitis.
Specifically, there is a trend of decreased recovery of S
pneumoniae resistant to penicillin from 41% to 29% and
an increase in beta-lactamase producing Hi n f l u e n z a e
from 33% to 39% [57].
The primary concern for H influenzae is ampicillin
resistance, mediated by the production of a beta-lacta-
mase. Approximately 19% of H influenzae produce a
beta-lactamase [63]. H influenzae remains predictably
susceptible to amoxicillin-clavulanate, the cephalospor-
ins, and the fluoroquinolones [63]. Trimethoprim-sulfa-
methoxazole (TMP/SMX) and clarithromycin resistance
reported from Canadian laboratories are approximately
14% and 2%, respectively. Higher levels of beta-lacta-
mase production in H influenzae and M catarrhalis
have been reported [62].
Almost 95% of M catarrhalis produce a beta-lacta-
mase resulting in penicillin resistance. Aside from the
amino-penicillins, M catarrhalis remains predictably
susceptible to virtually all other antibiotics.
Methicillin-resistant Staphylococcus aureus (MRSA) is
typically considered a multi-drug resistant pathogen.
MRSA had a 2.7% incidence in a study from Taiwan,
with nasal surgery being the most important risk factor
in adults and prior antibiotic use as the major risk factor
in children [64]. Community acquired MRSA (CA-
MRSA) strains are resistant to all beta-lactam agents,
but typically remain susceptible to TMP/SMX, doxycy-
cline, and clindamycin [65]. At least 1 study has demon-
strated that 4% of ABRS infections were associated with
CA-MRSA in the United States [66].
Clinicians should be cognizant of their local patterns
of resistance, as regional variations exist and some pro-
vinces report significantly higher rates of resistance than
others.
Treatment of ABRS
Role of Antibiotics
Statement 7: Antibiotics may be prescribed for ABRS to
improve rates of resolution at 14 days and should be
considered where either quality of life or productivity
present as issues, or in individuals with severe sinusitis
or comorbidities. In individuals with mild or moderate
symptoms of ABRS, if quality of life is not an issue and
neither severity criterion nor comorbidities exist, anti-
biotic therapy can be withheld.
Strength of evidence: Moderate
Strength of recommendation: Moderate
Rationale: Antibiotics may speed time to resolution of
symptoms in individuals with ABRS. However, overall
response rates evaluated at 14 days are similar for both
antibiotic-treated and untreated patients. Incidence of
side effects, mainly digestive, increases with antibiotic
administration.
The goals of treatment for ABRS are to relieve symp-
toms by controlling infection, decreasing tissue edema,
and reversing sinus ostial obstruction to allow drainage
of pus [67]. Treatment approaches are shown in Figure 1.
There is no evidence to support prophylactic antibiotic
therapy.
Many studies support the efficacy of antibiotics for
acute sinusitis. Results from a meta-analysis of 6 rando-
mized, placebo-controlled trials of amoxicillin or folate
inhibitors for acute sinusitis or acute exacerbation of
chronic sinusitis reported that antibiotics decreased risk
of clinical failure by half (risk ratio [RR] = 0.54; 95% CI,
0.37-0.79) compared with placebo treatment [68]. A
2009 meta-analysis of 6 placebo-controlled studies
reported a RR of 0.66 (95% CI, 0.44 to 0.98) for antibio-
tic use versus placebo, but noted questionable clinical
significance of the results as both groups had high cure
rates (80% placebo vs 90% antibiotics) [69]. Their con-
clusions agreed with the previous meta-analysis in that
clinical failure was significantly less frequent with anti-
biotics compared with placebo at 7 to 15 days of follow
up (RR, 0.74; CI, 0.65 to 0.84). In a third meta-analysis,
Figure 2 Trends in Antimicrobial Resistance in Canada [58,59].
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for the treatment of presumed ABRS were included
[70]. This study used a random effect model odds ratio
(OR) and reported a higher proportion of improvement
or cure (OR = 1.60, 95% CI, 1.31 to 1.96), but also a
higher rate of adverse events (OR = 1.94, 95% CI, 1.29-
2.92) for the antibiotic group versus the placebo group.
Although antimicrobial therapy is recommended for
the management of ABRS, this recommendation is not
without controversy [15,16,69-71]. In a meta-analysis of
studies enrolling patients with suspected ABRS not con-
firmed by imaging, laboratory testing, or cultures, analy-
sis of individual patient data resulted in an OR of 1.37
(95% CI, 1.13 to 1.66) for antibiotic use versus placebo
[72]. The calculated number needed to treat was 15.
Study authors concluded that clear justification for anti-
biotic treatment was lacking when ABRS was based on
clinical signs and symptoms. However, because the ana-
lysis included studies of patients who had not had
X-rays of the sinuses, and studies enrolled patients with
obvious viral infection, the meta-analysis missed an
opportunity to assess antibiotic efficacy in patients who
were clearly likely to benefit from treatment [73]. In
another meta-analysis of patients with symptoms of
acute sinusitis or rhinitis (10 studies) or acute rhinor-
rhea (3 studies), symptom duration averaged 8.1 days
(studies ranged from a median of 4.5 days to a mean of
15.4 days), and diagnosis was made from signs and
symptoms in over half of the studies. Although cure or
improvement rates were significantly better for the anti-
biotic group at 7 to 12 days, there was no difference
between treatment groups at 15 days, suggesting that
there was no difference between antibiotics and placebo
on patient outcomes. However, the meta-analysis
included studies of patients who likely had viral rhinosi-
nusits, in which antibiotics would be ineffective, thus
reducing the ability to assess drug efficacy on patients
most likely to benefit from treatment [74]. A long-term
objection to interpretation of placebo versus antibiotic
studies of acute sinusitis has been that the presumed
effectiveness of antibiotics in the management of bacter-
ial rhinosinusitis is diluted by the large number of indi-
viduals with viral disease participating in these trials.
However, a recent study has suggested that even in
cases of bacterial rhinosinusitis confirmed by sinus aspi-
rate obtained via puncture, antibiotics are no better
than placebo. In this study, patients with positive bacter-
ial cultures for ABRS reported that while 5-day moxi-
floxacin treatment led to numerically fewer clinical
failure rates versus placebo (19.2% vs 33.3%, respec-
tively), the difference was not statistically significant
(P = .122) [75]. Although the findings suggested a trend
for faster symptom resolution and lower failure rates for
antibiotic-treated individuals, they did not confirm the
absolute utility of antibiotic treatment compared with
placebo.
Combined, the various studies and meta-analyses do
suggest that antibiotic use, in the setting of ABRS, may
speed time to symptom resolution, but that little effect
is noted upon ultimate outcome, with similar rates of
resolution.
Take Home Points
Microbiology of ABRS:
￿ Main causative bacteria are Sp n e u m o n i a eand
H influenzae
￿ Minor causative bacteria are Moraxella catar-
hallis and S aureus
○ M catarrhalis is infrequent in the adult
population, but accounts for about 25% of
bacteria in children
￿ Anaerobic organisms appear to predominate in
acute sinusitis of odontogenic origin.
Role of antibiotic therapy in individuals with ABRS:
￿ Goals of treatment are to relieve symptoms by:
○ Controlling infection
○ Decreasing tissue edema
○ Reversing sinus ostial obstruction to allow
drainage of pus
￿ Antibiotics may be prescribed to improve rates
of symptom resolution
○ Overall response rates are similar for anti-
biotic-treated and untreated individuals.
￿ Antibiotics should be considered for
individuals:
○ With severe sinusitis or comorbidities
○ Where quality of life or productivity are
issues
￿ Incidence of side effects, mainly digestive,
increases with antibiotic administration.
Choosing an Antibiotic
Statement 8: When antibiotic therapy is selected, amox-
icillin is the first-line recommendation in treatment of
ABRS. In beta-lactam allergic patients, trimethoprim-
sulfamethoxazole (TMP/SMX) combinations or a
macrolide antibiotic may be substituted.
Strength of evidence: Option
Strength of recommendation: Strong
Statement 9: Second-line therapy using amoxicillin/
clavulanic acid combinations or quinolones with
enhanced gram positive activity should be used in
patients where risk of bacterial resistance is high, or
where consequences of failure of therapy are greatest, as
well as in those not responding to first-line therapy. A
careful history to assess likelihood of resistance should
be obtained, and should include exposure to antibiotics
in the prior 3 months, exposure to daycare, and chronic
symptoms.
Strength of evidence: Option
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Rationale: A comprehensive knowledge of the com-
mon etiologies associated with ABRS and the prevalence
of antibiotic resistance among these pathogens is para-
mount to select appropriate treatment. Because antibio-
tic selection will almost always be made in the absence
of bacterial cultures to guide management, activity
against the suspected pathogen should be considered.
Some important considerations for choosing an anti-
biotic include: the suspected or confirmed etiology,
medical history, Canadian patterns of antimicrobial
resistance, tolerability, convenience, and cost of treat-
ment. It should also be noted that an individual’sm e d i -
cal history is an important factor in treatment strategy.
Patients who are at increased risk of bacterial resistance
and complications due to underlying disease (eg, dia-
betes, chronic renal failure, immune deficiency) should
not be treated the same as otherwise healthy adults with
ABRS. Underlying systemic disorders place patients with
ABRS at increased risk of recurrence, antibiotic resis-
tance, and complications.
Studies have reported that expensive antibiotics were
no more effective than amoxicillin or folate inhibitors
for acute uncomplicated sinusitis in otherwise healthy
adults [68]. A meta-analysis of 3338 patients from 16
randomized comparative non-placebo studies concluded
that differences between antimicrobial agents are small
in otherwise healthy adults and adolescents, and there-
fore an inexpensive antibiotic should initially be chosen
[61]. Current evidence based on randomized controlled
trials suggest comparable efficacy amongst the antibio-
tics that have been approved for ABRS in Canada
[15,16,76-85]. These include amoxicillin, amoxicillin/cla-
vulanate, cefuroxime axetil, clindamycin, TMP/SMX,
clarithromycin, ciprofloxacin, levofloxacin, and moxi-
floxacin [86].
Selection between these different options may be diffi-
cult. Current recommendations are made on the basis
of presumed efficacy, risk of bacterial resistance, pre-
sence of complications, or cost of therapy.
First-line therapy is amoxicillin. Surveillance studies
demonstrate that resistance rates to amoxicillin by
streptococci remain low and a consistent response
remains predicted. Higher doses of amoxicillin are sug-
gested in suspected cases of penicillin-resistant Sp n e u -
moniae [62]. In patients with a questionable history of
beta-lactam allergy, skin testing may be appropriate to
confirm or deny sensitivity, as restricting use of penicil-
lin and penicillin derivatives may result in disadvantages
to the patient (ie, costs, side effects) [87]. First-line use
of macrolides should probably be limited to patients
allergic to penicillin.
Individuals with no clinical response within 72 hours
m a yb ep r e s u m e dt ob eu n r e s p o n s i v et ot h e r a p y .T h e
possibility of bacterial resistance should be suspected,
and therapy should be changed to a second-line
antibiotic.
Second-line therapy using fluoroquinolones with
enhanced gram-positive activity (ie, levofloxacin, moxi-
floxacin) or amoxicillin-clavulanic acid inhibitors as
initial management may be needed when there are con-
cerns of bacterial resistance or risk of complications in
cases of failure due to underlying disease.
Some populations have been found to be at greater
risk of harboring penicillin- and macrolide-resistant
streptococci. Depending on geographic location and
environment, S pneumoniae may be resistant to macro-
lides and TMP/SMX in nearly one third of cases [88].
Compared with control subjects, those with exposure to
daycare settings had a 3.79 (CI, 0.85 to 7.77) higher
odds of having penicillin-resistant infection [89]. It has
been demonstrated that individuals with invasive strep-
tococcal infections and antibiotic use within the past
3 months have a higher rate of antibiotic resistance, par-
ticularly in those treated with TMP-SMX (OR, 5.97) or
the macrolide azithromycin (OR, 2.78) [90]. Individuals
with antibiotic use within the past 3 months, chronic
symptoms greater than 4 weeks, or parents of children
in daycare have a higher risk of harboring penicillin-
and macrolide-resistant bacteria and should be treated
accordingly.
Second-line therapy used as initial management is also
needed in situations where a higher risk of complication
is associated with treatment failure because of underly-
ing systemic disease. Bacterial sinusitis of the frontal
and sphenoid sinuses pose a higher risk of complication
than maxillary and ethmoid sinusitis and require more
aggressive management and surveillance, with first-line
therapy consisting of a second-line agent [16]. Indivi-
duals with underlying immunosuppressive sites or medi-
cations, or with chronic medical conditions, are at
increased risk of complications if failure of therapy
occurs.
Statement 10: Bacterial resistance should be consid-
ered when selecting therapy.
Strength of evidence: Strong
Strength of recommendation: Strong
Rationale: Bacterial resistance rates to penicillin and
macrolide/streptogramin/licosamide families have
increased rapidly over the past decade to the extent that
penicillin and macrolide resistance is now common.
Failure of therapy secondary to resistant organisms has
led to poor clinical outcomes in several well-documen-
ted instances.
There is increasing evidence for the association
between antimicrobial resistance and adverse patient
outcomes [91,92]. Clinicians should enquire about
recent antibiotic use and choose an alternate class of
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Supporting this approach are new data that have shown
that therapy within the past 3 months is a risk factor for
pneumococcal resistance. The Toronto Bacterial Net-
work evaluated data from patients in 3339 cases of inva-
sive pneumococcal infection, of whom 563 had a history
of antibiotic therapy in the preceding 3 months where
the identity of the therapy was known [90]. In the study,
recent therapy with penicillin, macrolides, trimetho-
prim-sulfa, and quinolones (but not cephalosporin) was
associated with a higher frequency of resistance to that
same agent. Other patient subgroups identified as at risk
for infection with resistant bacterial strains included the
young (< 2 years of age), the elderly (> 65 years of age),
and those with severe underlying disease. These findings
emphasize the importance of taking a history of recent
antibiotic use and choosing an agent that differs from
what the patient had recently received.
Take Home Points
There are increasing rates of antibiotic resistance:
￿ Penicillin-, macrolide-, and multi-drug resistant
S pneumoniae in community-acquired respiratory
tract infections
￿ Be cognizant of local patterns of antibiotic
resistance, as regional variations exist.
Medical history influences treatment choice:
￿ Identify patients at increased risk of bacterial
resistance and complications
○ Those with underlying disease (eg, diabetes,
chronic renal failure, immune deficiency)
○ Those with underlying systemic disorders.
Considerations for choosing an antibiotic:
￿ Suspected or confirmed etiology
￿ Medical history
￿ Presence of complications
￿ Canadian patterns of antimicrobial resistance
￿ Risk of bacterial resistance
￿ Tolerability
￿ Convenience
￿ Cost of treatment.
Antibiotic choice:
￿ First-line: amoxicillin
○ In beta-lactam allergy: TMP/SMX or
macrolide
￿ Second-line: amoxicillin/clavulanic acid combina-
tion, or quinolones with enhanced gram-positive
activity (ie, levofloxacin, moxifloxacin)
○ For use where first-line therapy failed
(defined as no clinical response within
72 hours), risk of bacterial resistance is high,
or where consequences of therapy failure are
greatest (ie, because of underlying systemic
disease).
For uncomplicated ABRS in otherwise healthy
adults, antibiotics show comparable efficacy.
Statement 11: When antibiotics are prescribed, dura-
tion of treatment should be 5 to 10 days as recom-
mended by product monographs. Ultra-short treatment
durations are not currently recommended by this group.
Strength of evidence: Strong
Strength of recommendation: Moderate
Rationale: Some data support efficacy of shorter dura-
tions of therapy; however, none of these short durations
have been approved in Canada, and are thus not recom-
mended by this group.
Traditional approaches to antimicrobial management
of ABRS focus on courses of therapy of at least 10 days
duration [94]. The rationale for this length of therapy
originated from studies in tonsillopharyngitis. Potential
benefits of short-course therapy include improved com-
pliance, fewer adverse events, reduced risk of treatment
failure and bacterial resistance, and reduced cost. A
number of studies have investigated short-course ther-
apy with various antibiotics and have demonstrated
similar benefit as comparators (Table 6). These studies
have been performed using a variety of antibiotics, some
recommended, some not presently recommended in
these guidelines, and several either not or no longer
marketed in Canada. Of note is that in the United
States, a 1-day course of azithromycin reported compar-
able efficacy to the comparator [95]. Despite this result,
it is the opinion of the group that a recommendation
for ultra-short courses of therapy be reserved until
further supporting trials are performed.
It is of the opinion of the group that 10 days of ther-
apy with an antibiotic is sufficient. Evolution of the dis-
ease and symptom response remains similar regardless
of shorter or longer courses of antibiotics [104]. Thus,
absence of complete cure (improvement in symptoms
without complete disappearance of symptoms) at the
end of therapy should be expected and should not cause
an immediate prescription of a second antibiotic.
Alternatives to Antibiotics: Intranasal Corticosteroids (INCS)
as Monotherapy
Statement 12: Topical INCS can be useful as sole ther-
apy of mild-to-moderate ARS.
Strength of evidence: Moderate
Strength of recommendation: Strong
Rationale: Topical INCS offer an approach to hasten
resolution of sinus episodes and clearance of infectious
organisms by promoting drainage and reducing mucosal
swelling [105]. They are also used to decrease the fre-
quency and severity of recurrent episodes [106]. Con-
cerns regarding safety of treatment with INCS have not
been borne out as their use has not been associated
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by adverse events or increased rates of infection [105].
Two studies have identified a positive effect from the use
of an INCS as sole treatment modality on resolution of
ARS. A study of 981 patients with acute uncomplicated RS
randomized patients to receive mometasone furoate nasal
spray 200 mcg once daily or twice daily for 15 days, amox-
icillin 500 mg 3 times daily for 10 days, or placebo [107].
At 14 days, mometasone furoate twice daily significantly
improved symptom scores compared with placebo (P <
.001) and amoxicillin (P = .002). Symptom scores were sig-
nificantly improved beginning on day 2 with mometasone
furoate twice daily compared with amoxicillin and placebo.
Global response to treatment at day 15 was also signifi-
cantly improved with mometasone furoate twice daily
compared with amoxicillin and placebo. Although treat-
ment failure was lower with mometasone furoate twice
daily than with amoxicillin, the difference did not reach
statistical significance. In a study assessing quality of life
with the SinoNasal Outcome Test (SNOT)-20 question-
naire, 340 patients with acute uncomplicated RS were ran-
domized to mometasone furoate 200 mcg once daily or
twice daily, amoxicillin 500 mg 3 times daily, or placebo
[108]. After 15 days of treatment, the mometasone furoate
200 mcg twice daily group had significantly improved
scores on the SNOT-20 questionnaire compared with the
placebo group.
In another study, patients who presented with at least
2 of the Berg criteria were recruited from primary care
practices and randomized to 1 of 4 treatment arms:
antibiotic plus budesonide, antibiotic plus placebo bude-
sonide, placebo antibiotic plus budesonide, or placebo
antibiotic plus placebo budesonide [109]. Interventions
were amoxicillin 500 mg thrice daily for 7 days and
Table 6 Studies Investigating Alternative Therapy Duration, Dose, or Formulation
Agent Comparator Success Rate Side Effects
Duration
Azithromycin [96] Amoxicillin/clavulanate 88.8% and 84.9%, vs
84.9%
Higher for amox/clav
group
500 mg/d 1500/375 mg/d
3 or 6 days 10 days
Azithromycin [95]
microspheres
Levofloxacin 92.5% vs 92.8% Comparable
2 g 500 mg/d
1 day 10 days
Azithromycin [97] (meta-
analysis)
Amoxicillin, roxithromycin, cefaclor, erythromycin, amoxicillin/clavulanate,
clarithromycin, penicillin
Comparable Comparable
3 or 5 days
Levofloxacin [98] Levofloxacin >90% for both
groups
Comparable
750 mg/d 500 mg/d
5 days 10 days
Gatifloxacin [99]* Amoxicillin/clavulanate 74% and 80%, vs
72%
Comparable
400 mg/d 1750/250 mg/d
5 or 10 days 10 days
Gemifloxacin [100] Gemifloxacin 83.5% vs 84.2% Comparable
320 mg/d 320 mg/d
5 days 7 days
Dosing
Amoxicillin/clavulanate
[101]
Amoxicillin/clavulanate 88% vs 93% Comparable
500/125 mg 875/125 mg
Every 8 hours Every 12 hours
Formulation
Clarithromycin [102] ER Amoxicillin/clavulanate 98% vs 97% Comparable
1000 mg/d 1750/250 mg/d
14 days 14 days
*The fluoroquinolone, gatifloxacin was removed from the market following a study demonstrating potentially life-threatening glycemic events [103].
ER, extended release.
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Results showed no significant difference between treat-
ment arms (OR = 0.99, 95% CI, 0.57 to 1.73 for antibio-
tic vs placebo; OR = 0.93, 95% CI, 0.54 to 1.62 for
budesonide vs placebo). Authors concluded there was
no place for these agents in the treatment of ARS in pri-
mary care. However, because the median days of symp-
tom duration at presentation was shorter (7 days, with a
range of 4 to 14 days) than currently recommended, the
patient population may have included a greater propor-
tion than usual of viral rather than bacterial sinusitis
[110], thus limiting the ability to detect the benefit of
treatments on bacterial episodes.
Although there is limited evidence for and against the
use of INCS as monotherapy in the treatment of ABRS,
it remains an interesting treatment approach. INCS cur-
rently offers a novel option that may be explored based
on limited evidence suggesting benefit. In the context of
conflicting results between different trials, the use of
INCS with established dosing requirements indicated for
ABRS may be preferable. Additional clinical trials and
further experience in coming years will better discern its
role in the management of ABRS.
Management of Failures of First-Line Therapy
Statement 13: Treatment failure should be considered
when patients fail to respond to initial therapy within
72 hours of administration. If failure occurs following
use of INCS as monotherapy, antibacterial therapy
should be administered. If failure occurs following anti-
biotic administration, it may be due to lack of sensitivity
to, or bacterial resistance to, the antibiotic, and the anti-
biotic class should be changed.
Strength of evidence: Option
Strength of recommendation: Strong
Rationale: In patients managed with a topical corti-
costeroid as sole therapy, persistent bacterial infection
may be presumed and an antibiotic should be instituted,
according to guidelines for selection of an antibiotic.
Bacteriologic response to antibiotics should be expected
within 48 hours, thus symptoms should at least partially
attenuate by 72 hours. If symptoms persist unchanged
at this time, failure of response to antibiotic therapy
must be considered along with possible resistance [71].
Antibiotic therapy must be adjusted by switching to a
second-line antibiotic such as moxifloxacin or amoxicil-
lin/clavulanic acid combination or, in the case of a sec-
ond-line failure, to another antibiotic class.
Studies using in-dwelling catheters for serial sampling
of sinus fluid have reported the time course of antibio-
tics to eradicate pathogens as ranging from 24 to 72
hours [111-113]. In the absence of at least a partial clin-
ical response by 72 hours, bacterial resistance should be
suspected as one of the causes of failure and appropriate
measures should be instituted.
Take Home Points
Factors suggesting greater risk of penicillin- and
macrolide-resistant streptococci:
￿ Antibiotic use within the past 3 months
○ Choose an alternate class of antibiotic from
that used in the past 3 months
￿ Chronic symptoms greater than 4 weeks
￿ Parents of children in daycare.
When antibiotics are prescribed, treatment duration
should be 5 to 10 days as recommended by product
monographs.
￿ Improvement in symptoms without complete
disappearance of symptoms at the end of therapy
should be expected and should not cause an
immediate prescription of a second antibiotic.
Topical INCS can be useful as sole therapy of mild-
to-moderate ARS.
Treatment of first-line therapy failure:
￿ If symptoms do not at least partially attenuate
by 72 hours after INCS monotherapy:
○ Administer antibiotic therapy
￿ If symptoms do not at least partially attenuate
by 72 hours after antibiotic administration:
○ Bacterial resistance should be considered,
and
○ Antibiotic class should be changed
○ Switch to a second-line antibiotic, such as
▪ Moxifloxacin
▪ Amoxicillin/clavulanic acid combination
○ I nt h ec a s eo fas e c o n d - l i n ef a i l u r e ,s w i t c h
to another antibiotic class.
Adjunct Therapy
Statement 14: Adjunct therapy should be prescribed in
individuals with ABRS.
Strength of evidence: Option
Strength of recommendation: Strong
Statement 15. Topical intranasal corticosteroids
(INCS) may help improve resolution rates and improve
symptoms when prescribed with an antibiotic.
Strength of evidence: Moderate
Strength of recommendation: Strong
Statement 16. Analgesics (acetaminophen or non-
steriodal anti-inflammatory agents) may provide symp-
tom relief.
Strength of evidence: Moderate
Strength of recommendation: Strong
Statement 17. Oral decongestants may provide symp-
tom relief.
Strength of evidence: Option
Strength of recommendation: Moderate
Statement 18. Topical decongestants may provide
symptom relief.
Strength of evidence: Option
Strength of recommendation: Moderate
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relief.
Strength of evidence: Option
Strength of recommendation: Strong
Rationale: Analgesics, oral and topical decongestants,
topical INCS, and saline sprays or rinses can all help
relieve symptoms of both viral and bacterial infections
of the upper respiratory passages and can all be sug-
gested for symptomatic relief.
Ancillary and Alternative Therapies Recent reviews
suggest that the evidence for use of ancillary therapies is
relatively weak, as few prospective randomized clinical
trials have been performed to assess their effectiveness.
This does not necessarily mean that the therapies are of
no benefit, as these have long been a part of clinical
practice and may offer benefits. However, the lack of
good quality trials supporting their use requires the
incorporation of weaker levels of evidence, thus recom-
mendations are derived from extension from first princi-
ples and expert opinion.
Based on its effects on inflammation, topical INCS in
conjunction with antibiotic therapy have been assessed
for their effectiveness in improving resolution of signs
and symptoms of rhinosinusitis. In the Cochrane review
on this topic, 3 randomized, placebo-controlled studies
of the efficacy of 15- to 21-day courses of mometasone
furoate, fluticasone propionate, or budesonide for nasal
endoscopy-confirmed ARS found limited but positive
evidence for INCS as an adjuvant to antibiotics [105].
The symptoms of cough and nasal discharge were signif-
icantly improved (P < .05) through the second week of
treatment for patients receiving budesonide (50 mcg)
plus amoxicillin-clavulanate potassium compared with
those receiving placebo plus the antibiotic [114]. In
patients receiving mometasone furoate (200 mcg or 400
mcg twice daily) plus amoxicillin/clavulanate potassium,
total symptom score days 1 to 15 averaged and over the
21-day study period were significantly improved (P ≤
.017) compared with patients receiving placebo plus
antibiotic [115]. In a third study, a 21-day course of flu-
ticasone propionate (200 mcg) plus cefuroxime
improved the clinical success rate compared with pla-
cebo plus antibiotic (93.5% vs 73.9%, P = .009) as well
as the speed of recovery (6 days vs 9.5 days, P =. 0 1 )
[106]. No significant steroid-related adverse effects or
recurrence rates were reported. Topical INCS thus
appear to be safe and to afford an additional benefit
when antibiotics are used.
Oral decongestants have been shown to improve nasal
congestion and can be used until symptoms resolve,
provided there are no contraindications to their use.
Topical decongestant use is felt to be controversial and
should not be used for longer than 72 hours due to the
potential for rebound congestion [9].
There are no clinical studies supporting the use of
antihistamines in ABRS [71]. Although 1 randomized
controlled trial of human immunodeficiency virus-
infected patients with acute or chronic sinusitis reported
benefit with the mucolytic agent guaifenesin [116], no
benefit was reported in a randomized controlled trial in
healthy subjects [117].
There is limited evidence suggesting benefit of saline
irrigation in patients with acute sinusitis. Many studies
support the role of buffered hypertonic and buffered
normal nasal saline to promote mucociliary clearance.
In a study of patients with ABRS, thrice-daily irrigation
with 3% nasal saline improved mucociliary clearance
beginning in week 1 [118]. Moreover, subjects using
once daily hypertonic saline nasal irrigation reported
significantly improved symptoms, quality of life, and
decreased medication use compared with control sub-
jects [119]. However, the impact of saline sprays on
nasal airway patency is less clear, with studies variously
reporting no impact of saline sprays [120] and improved
patency with buffered physiological saline spray [121].
Their impact on symptom improvement is also uncer-
tain, with a study of hypertonic saline spray reporting
no improvement in nasal symptoms or illness duration
[122]. Saline therapy, either as a spray or high-volume
irrigation, has seen widespread use as adjunct treatment
despite a limited evidence base. Although the utility of
saline sprays remains unclear, the use of saline irrigation
as ancillary therapy is based on evidence of modest
symptomatic benefit and good tolerability.
Complementary and Alternative Medicine Recent
reviews have found limited evidence for alternative and
complementary medicine for ABRS [71,123]. Some of
these therapies include home-based foods such as soups,
fruit juices, teas, nutritional supplements, and herbal
remedies. Alternative practices that have failed to show
efficacy under scientific trial conditions include acu-
puncture, chiropracty, naturopathy, aromatherapy, mas-
sage, and therapeutic touch. Vitamin C preparations and
zinc lozenges are also felt to be controversial [71,123].
Studies of zinc lozenges for the common cold have pro-
duced mixed results. A recent meta-analysis of Echina-
c e ap r e p a r a t i o n sh a ss h o w ns o m ep o s i t i v ee f f e c t si n
reducing duration of respiratory tract symptoms [124].
A recent systematic review comparing placebo with
the herbal medications Sinupret or Bromelain as adjunct
therapy reported limited evidence of improved symp-
toms. Further, single randomized controlled trials on
Esbetritox, Mytrol, Cineole, and Bi Yuan Shu showed
some initial positive evidence [125]. A prospective ran-
domized controlled trial compared the homeopathic
medication Sinfrontal with placebo among 56 cases
and controls with radiograph-confirmed acute maxillary
sinusitis [126]. Participants were allowed saline
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tions; however antibiotics or other conventional thera-
pies for sinusitis were not permitted. From day 0 to 7,
Sinfrontal was associated with greater reduction in sinu-
sitis severity scores compared with placebo (P < .001).
On day 21, 68.4% of the Sinfrontal group had complete
resolution of symptoms versus 8.9% of the placebo
group. No recurrence was reported by the end of an 8-
week post-treatment observation period. Eight mild-to-
moderate adverse events were reported in the Sinfrontal
group. Although this data is of interest, further confir-
matory studies on the efficacy and safety of herbal med-
icines are needed before they can be recommended.
Physicians must inquire about the use of complemen-
tary therapies with their patients due to potential drug
interactions with conventional treatments and potential
toxicities related to the alternative/complementary
therapies themselves.
Management of Persistent Symptoms or Recurrent Acute
Uncomplicated Sinusitis
Statement 20: For those not responding to a second
course of therapy, chronicity should be considered and
the patient referred to a specialist. If waiting time for
specialty referral or CT exceeds 6 weeks, CT should be
ordered and empiric therapy for CRS administered.
Repeated bouts of acute uncomplicated sinusitis clearing
between episodes require only investigation and referral,
with a possible trial of INCS. Persistent symptoms of
greater than mild-to-moderate symptom severity should
prompt urgent referral.
Strength of evidence: Option
Strength of recommendation: Moderate
Rationale: Recurrent ABRS is defined as repeated
symptomatic episodes of acute sinusitis (≥4 episodes per
year) with clear symptom-free periods in between that
correspond to complete resolution between infections.
Individuals failing to respond to therapy or recurring
with symptoms early following therapy should be judged
to have CRS. CRS is an inflammatory disease with
symptoms that persist for 8 to 12 weeks. Referral to a
specialist is necessary to document CRS with endoscopy
or CT. Indications for referral include:
￿ Persistent symptoms of ABRS despite appropriate
therapy, or severe ABRS
￿ Treatment failure after extended course of
antibiotics
￿ Frequent recurrence (≥4 per year)
￿ Immunocompromised host
￿ Evaluation for immunotherapy of allergic rhinitis
￿ Anatomic defects causing obstruction
￿ Nosocomial infections
￿ Biopsy to rule out fungal infections, granulomatous
disease, neoplasms.
Furthermore, possible contributing factors (eg, under-
lying allergy, immunologic propensity for sino-pulmon-
ary infections) must be evaluated.
If confirmation of diagnosis by CT or specialty referral
to an ENT specialist for endoscopy is available within
6 weeks, administration of additional therapy may await
confirmation of the diagnosis. However, if CT or speci-
alty referral is unavailable within this timeframe, an
initial course of therapy for CRS should be given during
the wait for investigation and/or referral.
Prevention
Statement 21: By reducing transmission of respiratory
viruses, hand washing can reduce the incidence of viral
and bacterial sinusitis. Vaccines and prophylactic anti-
biotic therapy are of no benefit.
Strength of evidence: Moderate
Strength of recommendation: Strong
Rationale: Any strategy that reduces the risk of acute
viral infection, the most common antecedent to ABRS,
is considered a prevention strategy for ABRS. Because
ABRS follows an initial viral rhinitis/sinusitis, reductions
in the number of these episodes will help reduce the
incidence of bacterial sinusitis. Hand washing has been
shown to be effective in reducing person-to-person viral
transmission [127]. Patients with recurrent episodes may
benefit more from this strategy. In addition to hand
washing, educating patients about common predisposing
factors may be considered a preventative strategy.
Although vaccines for influenza have an invaluable
role in reducing the occurrence and transmission of
influenza, no such vaccine exists for the viruses respon-
s i b l ef o rU R T I s .T h e r ei sn oe v i d e n c et h a ti n f l u e n z ao r
pneumococcus vaccination reduces the risk of ABRS [9],
which likely reflects the variety of causative pathogens
associated with ABRS. Indeed, introduction of the 7-
valent pneumococcal vaccine in children led to a shift in
the causative pathogens among cases of adult acute
sinusitis [57]. However, individuals who meet current
guideline criteria for vaccinations are recommended to
keep up to date with their vaccines. Prophylactic anti-
biotics are also not effective in preventing viral episodes
or development of subsequent bacterial sinusitis, and
are not recommended as routine practice.
Immune Testing
Statement 22: Allergy testing or in-depth assessment of
immune function is not required for isolated episodes
but may be of benefit in identifying contributing factors
in individuals with recurrent episodes or chronic symp-
toms of rhinosinusitis.
Strength of evidence: Moderate
Strength of recommendation: Strong
Rationale: Recurrent episodes of ABRS may have
underlying contributing factors, including allergic
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with CRS or frequent episodes of ARS had a 57% preva-
lence of positive skin allergy tests [128]. Another study
showed that 84% of patients who had surgery for CRS
had a positive allergy test, and 58% had multiple aller-
gen sensitivities [129]. Such patients may have increased
susceptibility to inflammation of the nose and paranasal
sinuses [130]. However, in the treatment of ABRS in pri-
mary care, allergy testing is not required for investigat-
ing or resolving acute episodes.
Take Home Points
Adjunct therapy may provide symptom relief and
should be prescribed in individuals with ABRS:
￿ Topical intranasal corticosteroids (INCS)
￿ Analgesics (acetaminophen or non-steriodal
anti-inflammatory agents)
￿ Oral decongestants
￿ Topical decongestants
￿ Saline irrigation.
The goal of prevention strategies is to reduce the of
risk acute viral infection, the most common antece-
dent to ABRS.
￿ Techniques:
○ Handwashing
○ Educating patients on common predispos-
ing factors.
For patients with recurrent episodes of ABRS, con-
sider underlying contributing factors:
￿ Allergy testing to detect allergic rhinitis
￿ In-depth assessment of immune function to
detect immune deficiencies.
Chronic Rhinosinusitis (CRS)
Adult CRS prompts an estimated 18 to 22 million
annual office visits and 545 000 annual emergency room
visits in the United States [131]. In a survey study,
patients with CRS reported more bodily pain and worse
social functioning than patients with other chronic con-
ditions such as chronic obstructive pulmonary disease,
congestive heart failure, and back pain [132]. The
impact of CRS on patient quality of life is comparable in
severity to that of other chronic conditions. As with
other chronic diseases, CRS should be proactively
managed.
Definition and Diagnosis
Statement 23: CRS is diagnosed on clinical grounds but
must be confirmed with at least 1 objective finding on
endoscopy or computed tomography (CT) scan.
Strength of evidence: Weak
Strength of recommendation: Strong
Rationale: Symptoms of CRS alone are not sufficient
to diagnose CRS because they can be nonspecific and
mimicked by several disease entities (eg, upper
respiratory tract infection [URTI], migraine). Confir-
mation of sinus disease using an objective measure is
required. Conversely, in the absence of symptoms,
diagnosis of CRS based on radiology alone is not
appropriate because of a high incidence of radiological
anomalies on CT scans in normal individuals. Thus,
the presence of symptoms plus an objective finding
are necessary.
CRS may be defined as an inflammatory disease invol-
ving the nasal mucosa and paranasal sinuses [133]. CRS
is a symptom-based diagnosis supported by objective
documentation of disease by physical findings and diag-
nostic imaging or sinonasal endoscopy [9,18,133-137].
An algorithm for the diagnosis and management of CRS
is presented in Figure 3.
Take Home Points
Impact of CRS on patients:
￿ Significant bodily pain and impaired social
functioning
￿ Quality of life is comparable in severity to that
of other chronic conditions
￿ As a chronic condition, CRS should be proac-
tively managed.
CRS is an inflammatory disease involving the nasal
mucosa and paranasal sinuses.
￿ Symptoms are usually of lesser intensity than
those of ABRS
￿ Symptoms present for 8-12 weeks.
Symptoms of CRS
Symptoms of CRS are usually of lesser intensity than
those of acute bacterial rhinosinusitis (ABRS) but their
duration exceeds the 4 weeks commonly used as the
upper limit for the diagnosis of ABRS. A diagnosis of
CRS is probable if 2 or more major symptoms are pre-
sent for at least 8 to 12 weeks along with documented
inflammation of the paranasal sinuses or nasal mucosa
(Table 7) [9,21,138].
CRS can be further categorized based on the
absence or presence of nasal polyps (CRS without
nasal polyps, CRSsNP; or CRS with nasal polyps,
CRSwNP) [137]. Although both are characterized by
mucopurulent drainage and nasal obstruction,
CRSsNP is frequently associated with facial pain/pres-
sure/fullness whereas CRSwNP is frequently character-
ized by hyposmia.
A diagnosis of CRSsNP requi r e st h ep r e s e n c eo ft h e
following:
￿ At least 2 symptoms and
￿ Inflammation (eg, discolored mucus, edema of
middle meatus or ethmoid area) documented by
endoscopy and
￿ Absence of polyps in the middle meatus (by endo-
scopy) and/or
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osteomeatal complex on endoscopy or rhinosinustis
confirmed by CT imaging.
A diagnosis of CRSwNP requires the presence of:
￿ At least 2 symptoms and
￿ The presence of bilateral polyps in the middle
meatus confirmed by endoscopy and
￿ Bilateral mucosal disease confirmed by CT imaging
[137].
Further sub-definitions of sinonasal polyposis include
subtypes related to the presence of acetylsalicylic acid
(ASA) sensitivity or the presence of eosinophilic mucin,
with or without documented immunoglobulin E (IgE)-
mediated fungal hypersensitivity [21]. Both subtypes are
recalcitrant to treatment.
Take Home Points
Major symptoms of CRS:
￿ Facial Congestion/fullness
￿ Facial Pain/pressure/fullness
￿ Nasal Obstruction/blockage
￿ Purulent anterior/posterior nasal Drainage (dis-
charge may be nonpurulent, nondiscolored)
￿ Hyposmia/anosmia (Smell).
Diagnosis of CRS requires all of the following:
￿ Presence of ≥ 2 major symptoms (CPODS)
￿ Symptoms (CPODS) present for at least 8 to 12
weeks
Figure 3 Algorithm for the Diagnosis and Management of CRS.
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sinuses or nasal mucosa
○ Endoscopy
○ CT scan, preferably in coronal view.
CRS subtypes:
￿ CRS without nasal polpys (CRSsNP), frequently
characterized by:
○ Mucopurulent drainage
○ Nasal obstruction
○ Facial pain/pressure/fullness
￿ CRS with nasal polyps (CRSwNP), frequently
characterized by:
○ Mucopurulent drainage
○ Nasal obstruction
○ Hyposmia.
A diagnosis of CRSsNP requires the presence of the
following:
￿ At least 2 symptoms and
￿ Inflammation (eg, discolored mucus, edema of
middle meatus or ethmoid area) documented by
endoscopy and
￿ Absence of polyps in the middle meatus (by
endoscopy) and/or
￿ Purulence originating from the osteomeatal
complex on endoscopy or rhinosinustis con-
firmed by CT imaging.
A diagnosis of CRSwNP requires the presence of:
￿ At least 2 symptoms and
￿ The presence of bilateral polyps in the middle
meatus confirmed by endoscopy and
￿ Bilateral mucosal disease confirmed by CT
imaging.
Physical Examination
Statement 24: Visual rhinoscopy assessments are useful
in discerning clinical signs and symptoms of CRS.
Strength of evidence: Moderate
Strength of recommendation: Moderate
Rationale: Assessment of the individual with chronic
nasal symptoms necessarily includes physical examina-
tion of the nasal cavity. Physical examination should be
performed with equipment affording good illumination.
Although a headlight and nasal speculum is optimal, an
otoscope affords an adequate view.
A systematic assessment, evaluation or examination of
the nasal septum, inferior turbinates, and middle meatal
area should be performed. In the nasal septum, drying
crusts, ulceration, bleeding ulceration, and perforation
should be identified when present. Attention must be
devoted to the identification of anatomic obstructions,
unusual aspects of the nasal mucosa, hypertrophy of the
turbinates, and/or presence of secretions or nasal
masses. Significant septal deflections should be noted.
Additionally, color of the nasal mucosa and presence of
dryness or hypersecretion should be noted. The normal
mucosa is pinkish-orange with a slight sheen demon-
strating hydration. Presence of an irregular surface,
crusts, diffusely hemorrhagic areas, vascular malforma-
tions or ectasias, or bleeding in response to minimal
trauma, is abnormal and should warrant specialist
assessment.
The turbinates should be carefully inspected. Inferior
turbinates should be assessed for hypertrophy. The area
of the middle turbinate and the middle meatus adjacent
to it between the septum and the lateral nasal wall
should be visualized and inspected carefully for the pre-
sence of secretions or masses such as nasal polyps. This
area may be difficult to visualize and visualization of
these areas may be improved by performing vasocon-
striction of the nose using a decongestant product such
as Dristan
® or Otrivin
®.
Visualization is further improved by the use of sino-
nasal endoscopy. Sinonasal endoscopy allows for
improved visualization of the middle meatal area, the
posterior portion of the nose, and nasopharynx and
allows better identification of nasal polyposis in the
early stages. Although an almost integral component of
specialist assessment, it requires specialized equipment
and appropriate training. Endoscopy can reveal edema
or obstruction of the middle meatus [21]. By allowing
visualization of the nasal cavity and sinus openings,
nasal endoscopy permits identification of posterior sep-
tal deviation and polyps and secretions in the posterior
nasal cavity, middle meatus, sphenoethmoidal recess,
and direct aspiration of secretions for analysis and cul-
ture (see below, endoscopically-directed middle meatus
[EDMM]) [9].
Table 7 CRS Diagnosis Requires the Presence of at Least 2 Major Symptoms*
Major Symptom
C Facial Congestion/fullness
P Facial Pain/pressure/fullness
O Nasal Obstruction/blockage
D Purulent anterior/posterior nasal Drainage (discharge may be nonpurulent, nondiscolored)
S Hyposmia/anosmia (Smell) [9,21,136].
*A diagnosis requires at least 2 CPODS, present for 8 to 12 weeks, plus evidence of inflammation of the paranasal sinusus or nasal mucosa.
CRS is diagnosed on clinical grounds but must be confirmed with at least 1 objective finding on endoscopy or CT scan.
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Statement 25: In the few situations when deemed
necessary, bacterial cultures in CRS should be per-
formed either via endoscopic culture of the middle mea-
tus or maxillary tap but not by simple nasal swab.
Strength of evidence: Option
Strength of recommendation: Strong
Rationale: Endoscopic cultures of the middle meatus
are less invasive than maxillary tap. To be of value,
these cultures require skilled practitioners to perform
the endoscopic examination and sampling to avoid con-
tamination from normal nasal flora or from adjacent
structures. Simple swab nasal cultures are of little pre-
dictive value. Of note is that when purulent secretions
are observed, these should be sampled directly, as cul-
ture resulting from a thin stream of pus and an adjacent
area can differ. Also, since all specimens are potentially
contaminated to varying degrees, proper specimen col-
lection, transport, storage, and processing are key.
Involvement of bacterial biofilm can be difficult to
detect, and identification of pathogens relies on analyz-
ing tissue samples with either electron or confocal scan-
ning laser microscopy (CSLM), or indirectly by
analyzing the DNA signature for biofilm-forming genes
[139,140]. These tests remain primarily research tools
and are not currently available in the clinical setting.
Maxillary Sinus Aspirate (MSA) MSA is considered
the gold standard for bacterial recovery in acute and
chronic sinusitis, but there are still issues of concern.
Because the procedure is invasive, it is usually per-
formed by specialists rather than in family practice, and
even then only rarely. MSA is recommended if there are
serious complications, such as orbital infection, intracra-
nial extension of the infection, or in patients with noso-
comial sinusitis. MSAs are usually obtained by puncture
through the canine fossa or inferior meatus and are sub-
ject to contamination by oral or nasal flora during col-
lection. Because pathogens in various sinuses may differ,
MSAs are limited in only being representative of the
maxillary sinus. Other concerns with MSAs include
patient compliance, discomfort, bleeding, secondary
infection, and (rarely) injury to the infraorbital nerve or
orbit.
Nasal and Postnasal Discharge Culture Most studies
have shown poor correlation of nose and throat cultures
with MSAs, and these cultures are generally not recom-
mended in patients with acute or chronic sinusitis.
Endoscopically-Directed Middle Meatus Culture
(EDMM) EDMM requires specialist expertise and
equipment. It is safe and usually painless. The area
sampled (the middle meatus) contains the ostiomeatal
complex, which provides a common drainage pathway
for the maxillary, ethmoid, and frontal sinuses. EDMM
cultures are therefore representative of frontal, ethmoid,
and maxillary sinuses. However, as with MSAs, EDMMs
are subject to contamination with resident nasal flora
(including anaerobes), which makes their interpretation
subject to clinical situation. Also, pathogenic bacteria
such as S. pneumoniae, H. influenzae, and S. aureus may
be isolated from asymptomatic patients in the carrier
state. The significance of this carrier status is uncertain
but in the absence of symptoms, treatment is rarely
initiated. EDMM swab and MSA have been shown to be
equivalent for detection of pathogens and likelihood of
contamination [140,141].
Fungal Pathogens If invasive fungal sinusitis is sus-
pected, prompt diagnosis and treatment are essential.
Culture must be requested promptly because these
infections are life threatening and usually require emer-
gency surgery. However, results of culture are rarely
available to assist with decision-making, and diagnosis is
most frequently made on the basis of Gram staining and
frozen sections demonstrating the characteristic branch-
ing hyphae arrangement. Biopsies for Gram stain and
culture (aerobic and anaerobic bacterial culture plus
fungal culture) and for histopathology and special stains
are key.
Conclusions for Bacterial Recovery Although postna-
sal/nasal discharge is common, routine cultures of such
are discouraged and empiric therapy is recommended. If
a patient fails multiple courses of empiric therapy, they
should be referred to an otolaryngologist for evaluation,
which usually includes sinonasal endoscopy. If purulent
material is identified, diagnostic culture may be made by
EDMM. When situation warrants it, such as for compli-
cations or in nosocomial intensive care unit sinusitis,
MSA may be performed.
Radiological Imaging
Statement 26: The preferred means of radiological ima-
ging of the sinuses in CRS is the CT scan, preferably in
the coronal view. Imaging should always be interpreted
in the context of clinical symptomatology because there
is a high false-positive rate.
Strength of evidence: Moderate
Strength of recommendation: Strong
Rationale: Conventional X-ray images do not ade-
quately image the ethmoid sinuses or the osteomeatal
complexes, which are key to the development and per-
sistence of CRS, and when clinically indicated, may thus
be assessed with CT scanning. However, positive CT
findings alone are not indicative of CRS in the absence
of signs or symptoms given the high prevalence of
mucosal changes accompanying URTIs and/or asympto-
matic changes in the non-diseased population.
CT is an important means of providing objective evi-
dence for the diagnosis of CRS but must absolutely be
correlated with clinical and endoscopic findings to
interpret them meaningfully. Several studies have
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tor for CRS [31-33]. Further studies have reported
either no correlation [142] or a low correlation
[143-145] between symptoms and CT findings. These
results reflect the need to interpret imaging results in
the context of persistent symptoms to provide an accu-
rate diagnosis. Thus CT should not be used as the sole
criteria for determining the need for surgical interven-
tion, but rather should be used as an objective tool for
confirming the diagnosis of CRS and for surgical plan-
ning. CT scans should be ordered after failure of maxi-
mal medical management and/or for the planning of
surgery. A complete CT scan should be obtained if the
physician is contemplating surgical intervention, and the
scan ideally should be at a minimum resolution of
3 mm coronal slices, if not more detailed. Reconstruc-
tion in the sagittal plane may help with performance of
surgery, particularly in the area of the frontal sinus.
Take Home Points
Visual assessments include:
￿ Physical examination of the nasal cavity with
equipment affording good illumination
○ Headlight and nasal speculum
○ Otoscope.
Examination of:
￿ The nasal septum
○ Identify drying crusts, ulceration, bleeding
ulceration, and perforation, anatomic
obstructions, unusual aspects of the nasal
mucosa, and/or presence of secretions or
nasal masses
○ Note significant septal deflections, and
color of the nasal mucosa and presence of
dryness or hypersercretion. The normal
mucosa is pinkish-orange with a slight sheen
demonstrating hydration
○ Presence of an irregular surface, crusts, dif-
fusely hemorrhagic areas, vascular malforma-
tions or ectasias, or bleeding in response to
minimal trauma, is abnormal and should
warrant specialist assessment
￿ Inferior turbinates:
○ Assess for hypertrophy
￿ Middle meatal area:
○ I n s p e c tt h ea r e ao ft h em i d d l et u r b i n a t e
and the middle meatus adjacent to it between
the septum and the lateral nasal wall for the
presence of secretions or masses such as
nasal polyps
○ Visualization of these areas may be
improved by performing vasoconstriction of
t h en o s eu s i n gad e c o n g e s t a n tp r o d u c t( e g ,
Dristan
® or Otrivin
®). Sinonasal endoscopy
may improve visualization.
Pathophysiology
Statement 27: CRS is an inflammatory disease of
unclear origin where bacterial colonization may contri-
bute to pathogenesis. The relative roles of initiating
events, environmental factors, and host susceptibility
factors are all currently unknown.
Strength of evidence: Weak
Strength of recommendation: Moderate
Rationale: Intense inflammation with eosinophilic,
neutrophilic, and lymphocytic infiltrations and upregula-
tion of numerous T helper (Th) cell type 2-associated
cytokines has been well documented in biopsy samples
of CRS. The disease process has several similarities with
asthma, including infiltration of a similar population of
inflammatory cells, cytokine profile, and evidence of tis-
sue remodeling. The role of bacteria remains imprecise
in the face of frequent negative cultures, however a role
for colonization of S. aureus contributing to disease via
superantigenic stimulation has been proposed. Emerging
evidence on bacterial biofilms may explain frequent
negative cultures and change our future understanding
of the role of bacteria in CRS.
The last 10 years have witnessed new insights into the
inflammatory mechanisms of CRS. Investigation of the
inflammatory roles of cytokines and chemokines has
shed considerable light on the pathogenesis of this dis-
ease. It is now widely documented that T lymphocytes
and the activated eosinophils are prominent within the
sinus mucosa of patients with CRS, especially in atopic
patients. Recruitment and activation of the inflammatory
cell infiltrate has largely been attributed to the effects of
Th2 cytokines (namely interleukin [IL]-4, IL-5, IL-13,
and granulocyte monocyte-colony stimulating factor),
and the eosinophil-associated chemokines, eotaxin, and
monocyte chemotactic proteins.
Evidence that CRS subtypes have distinct pathogenetic
mechanisms, and may represent distinct diseases, has
been suggested in biomarker studies of nasal secretions.
In 1 study, IL-5 and nasal IgE were significantly asso-
ciated with CRSwNP but not with CRSsNP or acute rhi-
nosinusitis (ARS) [146]. Another study extended these
findings, reporting that CRSwNP had Th2 polarization
and a higher prevalence of IL-5, IgE, eosinophils,
eotaxin, and eosinophil cationic protein, whereas
CRSsNP had Th1 polarization and higher levels of inter-
feron-gamma and transforming growth factor (TGF)-
beta [147]. These results indicate that cytokine and
mediator profiles may be useful in differentiating
between disease entities.
Recruitment and persistence of adaptive immune
responses resulting in the development of the clinical
symptoms characteristic for CRS may reflect dysfunction
of the nasal epithelium and its subsequent inability to
properly coordinate immune responses to foreign matter
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have altered expression and function of Toll-like recep-
tors, production of factors involved in control of innate
immunity, and in the functional regulation of local
adaptive immunity [148-151].
Due to the heterogeneity of the pathogenesis and the
clinical presentation of CRS, it has been suggested that
CRS be considered a syndrome with persistent charac-
teristic symptoms instead of as a discrete disease entity
[148].
Allergy and Inflammation
T h ei n f l a m m a t o r yd i s e a s eo ft h en a s a la n dp a r a n a s a l
sinus mucosa is classified as allergic and non-allergic,
depending on the presence or absence of atopy. The
immunopathologic mechanisms underlying the develop-
ment of CRS in allergic patients are largely related to
the effects of Th2 cytokines and their corresponding
receptors. In contrast, a combination of Th1 and Th2
cytokines seems to orchestrate the inflammatory
response in non-allergic CRS patients. Similar observa-
tions have been made in CRS with and without nasal
polyposis [152,153]. Despite these distinct mechanisms,
the common outcome in CRS, in both atopic and non-
atopic patients, is an intense eosinophilic infiltration.
Production of IgE, while present in allergic CRS, has
also been reported in CRS even in the absence of history
of allergy and the presence of a negative skin test [154].
Remodeling, or structural changes, associated with
chronic inflammation include epithelial changes,
increased deposition of extracellular matrix proteins (eg,
collagen), and increased expression of growth factors
and profibrotic cytokines (eg, IL-6, IL-11, IL-17, TGF-
beta, and platelet-derived growth factor) [155,156].
The Upper - Lower Airway Relationship
The current one-airway or united airway concept is sup-
ported by anatomical links and similarities in histology,
pathophysiology, and immune mechanisms. Approxi-
mately 40% of patients with CRS have asthma [157,158]
and many more demonstrate bronchial hyperreactivity
without overt symptoms, supporting a clinical link
between these 2 conditions. Conversely, asthmatic
patients often report the presence of upper airway dis-
ease and the frequency increases with severity of
asthma. The mechanism of the relationship is unclear.
Eosinophilic inflammation is a common link between
these 2 diseases, which could be consistent with the the-
ory of united airways. The systemic nature of airway
inflammation is supported by data showing that immune
responses within the airway are paralleled by similar
immuno-inflammatory events in peripheral blood and
bone marrow. Allergen provocation of either the upper
or lower airway induces not only local changes but simi-
lar findings in the other airway, peripheral blood, and
bone marrow [159]. Eosinophilic inflammation, airway
remodeling, and cytokine patterns are similar through-
out the airway. Studies have shown that increased eosi-
nophils in blood and sputum and elevated nitric oxide
levels in asthmatics correlate with the severity of sinus
CT abnormalities (reflected by sinus CT scores).
Bacteriology
Statement 28: Bacteriology of CRS is different from that
of ABRS.
Strength of evidence: Moderate
Strength of recommendation: Strong
Rationale: Bacteriology of CRS is not as well under-
stood as that of ABRS. Frequent negative cultures, high
levels of S aureus and coagulase-negative isolates, and a
questionable role of anaerobes complicate the picture of
CRS. Although the presence of S aureus and coagulase-
negative Staphylococci (CNS) have long been believed to
suggest contamination, demonstration of Sa u r e u s -
derived enterotoxin thought to participate in the devel-
opment of CRS potentially implicates this agent as an
important pathogen in CRS. Association of in vitro bio-
film-producing capacity and poor outcomes in post-
endoscopic sinus surgery (ESS) patients also support a
role for these bacteria in disease pathogenesis [160,161].
Normally, the nasal vestibule is colonized with skin
flora and frequently contains Sa u r e u s . In healthy con-
trol subjects, the middle meatus contains a mixture of
skin and mucosal flora, such as CNS, diphtheroids, viri-
dans group streptococci, Pa c n e sand other anaerobes,
and also contains bacteria capable of behaving as patho-
gens in disease settings, such as Sa u r e u s , Hi n f l u e n z a e ,
and S pneumoniae.
The main pathogens recovered in chronic sinusitis
include Sa u r e u s , Enterobacteriaceae spp, and Pseudo-
monas spp, and less commonly Sp n e u m o n i a e , Hi n f l u -
enzae, and beta hemolytic streptococci. It is thought
that CNS may be pathogenic when present in large
amounts, and when seen with neutrophils in the Gram
stain or on histopathology.
The role of bacteria in CRS has been difficult to
understand because bacteria have been cultured in only
50% of patients undergoing primary ESS [162]. Addi-
tionally, the flora recovered is different from that in
ABRS, with high recovery rates of Sa u r e u sand Pseudo-
monas aeruginosa. The effect by which these known
pathogens exert their effect is only beginning to be
explained. Despite the fact that Sa u r e u scan be identi-
fied in 20% to 30% of nasal or sinus cultures in healthy
Caucasians, S aureus has nevertheless been suggested to
act as a pathogen in CRS with nasal polyposis, either via
a superantigen-driven mechanism [163-165], interfer-
ence with tissue metalloproteinase function [147], or
induction of the low-affinity glucocorticoid receptor-
beta [166]. Pseudomonas aeruginosa is a frequent
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almost ubiquitous in adult patients with cystic fibrosis
(CF). Its action is via a number of toxins and proteases.
Haemophilus influenza, a respiratory pathogen pre-
viously believed to be important mainly in acute infec-
t i o n s ,m a ya l s ob ei n v o l v e d .I nas t u d yo fb a c t e r i a l
biofilms in CRS using CSLM with fluorescent in-situ
hybridization, the principal pathogen identified was H
influenza, despite the fact that it was not recovered in
any of the simultaneously performed conventional sinus
cultures [139]. However, it was also recovered in 2 of 5
of the asymptomatic control specimens, reinforcing the
importance of other factors such as host susceptibility
to the development and persistence of inflammation in
CRS. These reports require additional confirmation.
Bacterial resistance alone cannot explain persistence
of disease. Persistence of bacteria intracellularly or as
bacterial biofilms may provide some answers by fur-
nishing what seems to many as the ‘missing link’
between bacterial presence and inflammation in CRS.
The intracellular persistence of Sa u r e u shas been
shown to occur between exacerbations of disease in
patients colonized with this agent [167]. The presence
of bacterial biofilms has been demonstrated in CRS
patients in several studies, and may explain negative
cultures [168-170]. Arguing for a functional link
between bacterial biofilms and CRS, 2 studies have
reported poor outcomes in post-ESS patients harboring
Sa u r e u sor Pseudomonas aeruginosa with the capacity
to form a biofilm in vitro [160,171]. This was not the
case for CNS, reinforcing the concept that it is not the
presence of the biofilm itself but the specific patho-
genic bacteria that is responsible for this phenomenon.
This finding was confirmed by a separate group of
investigators [171].
Fungi in CRS
Fungi frequently colonize the nasal airways in healthy
subjects, and there have been conflicting reports of the
role of fungi in CRS [172,173]. The presence of several
different species of fungi in both individuals with CRS
and healthy controls has been reported, with responses
to Alternaria sp only in those individuals suffering from
CRS. Large-scale placebo-controlled trials have failed to
demonstrate a beneficial effect of topical irrigation with
an antifungal.
Invasive fungi (eg, Aspergillus spp and Zygomycetes
[Rhizopus, Mucor, Absidia] )c a nb ea g g r e s s i v ea n da r e
more commonly seen in immunocompromised patients
(eg, bone marrow transplant, diabetic, immunosuppres-
sive agents); these are uncommon in immunocompetent
hosts. Chronic invasive fungal sinusitis, a less severe dis-
ease, can be caused by Candida spp, Aspergillus spp,
Pseudallescheria boydii, and is seen mostly in immuno-
compromised hosts.
Take Home Points
CRS is an inflammatory disease of unclear origin.
Contributors may include:
￿ Bacterial colonization
￿ Bacterial biofilms
￿ Eosinophilic, neutrophilic, and lymphocytic
infiltrations
￿ Upregulation of numerous Th2-associated
cytokines
￿ Tissue remodeling (epithelial changes,
increased extracellular matrix proteins, growth
factors, and profibrotic cytokines)
￿ Atopy determines allergic versus nonallergic
classification.
Bacteriology of CRS is different from that of ABRS:
￿ Not as well understood as that of ABRS
￿ The main pathogens include:
○ S aureus
○ Enterobacteriaceae spp
○ Pseudomonas spp
￿ Less common:
○ S pneumoniae
○ H influenzae
○ Beta hemolytic streptococci.
○ Coagulase-negative Staphylococci (CNS).
Predisposing Factors
Statement 29: Environmental and physiologic factors
can predispose to development or recurrence of chronic
sinus disease. Gastroesophageal reflux disease (GERD)
has not been shown to play a role in adults.
Strength of evidence: Moderate
Strength of recommendation: Strong
Rationale: Although the mechanism has not been
fully explained, a high prevalence of allergic rhinitis has
been documented in CRS patients. In addition, asthma
co-occurs in 40% to 70% of patients with CRS [158].
Ciliary dysfunction and immune dysfunction have also
been associated with CRS [135].
Physiologic factors include conditions in which muco-
ciliary clearance is defective (due to either an abnormal-
ity of the cilia or mucus rheology), ostia patency is lost,
or immune deficiency is present [174]. Key factors of
sinonasal defense (cilia, mucus, ostia) may become
abnormal in conditions such as allergic rhinitis, non-
allergic rhinitis, atrophic rhinitis, hormonally-induced or
drug-induced rhinitis, occupational rhinitis, ciliary dyski-
nesia, and nasal polyposis obstructing the ostia.
Allergy
Epidemiological data show an increased prevalence of
allergic rhinitis in patients with CRS, but the role of
allergy in the development of CRS remains unclear
[129,175]. The theory that swelling of the nasal mucosa
in allergic rhinitis at the site of the sinus ostia
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quent rhinosinusitis has not been confirmed. Occupa-
tional exposures may include workplace allergens
(animals, foodstuffs, chemicals), irritants, and cigarette
smoke. The contribution of these irritants is unclear.
Aspirin Sensitivity
Aspirin (acetylsalicylic acid [ASA])-exacerbated respira-
tory disease is an inflammatory disease with underlying
asthma, nasal polyps, and sinusitis [176]. The combined
presence of asthma, nasal polyps, and ASA sensitivity is
termed Samter’s triad. ASA intolerance is found with
variable frequency and severity in patients with rhinosi-
nusitis with or without nasal polyps. Patients with this
triad generally are sensitive to all cross-reacting non-
steroidal anti-inflammatory agents (eg, ibuprofen).
Patients may have life-threatening asthma attacks in
addition to severe recalcitrant sinusitis. Although the
precise mechanism is unclear, it may be related to inhi-
bition of an enzyme cyclooxygenase (COX) with subse-
quent shunting of arachidonic acid metabolism to the
lipoxygenase pathway, culminating in massive leuko-
triene release. Other inflammatory products may also be
involved.
Gastroesophageal Reflux Disease (GERD)
GERD is a common gastrointestinal problem possibly
associated with both upper and lower airway disease. A
proposed mechanism suggests that GERD causes reflux
of gastric acid into the pharynx and subsequently to the
nasopharynx causing inflammation of the sinus ostium
leading to sinusitis [177]. Although an association
between gastroesophageal reflux and sinusitis has been
suggested [178], no definitive causal relationship has
been shown in a well-performed controlled study in
adults [179]. Due to this lack of evidence, the hypothesis
that GERD contributes to sinusitis cannot be supported.
Cystic Fibrosis
CF is caused by mutations within the CF transmem-
brane conductance regulator gene leading to altered
chloride transport in secretions. In addition to the vis-
cous mucus that blocks the lungs and digestive system,
CF is also characterized by inflammation, sinus block-
age, and polyposis. An estimated 5% to 86% of children
with CF have nasal polyposis [180]. Approximately half
of CF carriers also reported CRS, suggesting an interac-
tion between the CF gene mutation and CRS [181]. Of
interest is that biopsy samples in CF show a predomi-
nantly neutrophilic infiltrate, suggesting that develop-
ment of nasal polyposis may occur via a different
pathogenic mechanism, however both Th1 and Th2
cytokine profiles have been reported in patients with
CRS [182].
Take Home Points
Both environmental and physiologic factors that can
predispose to/be associated with CRS:
￿ Allergic rhinitis
￿ Asthma
￿ Ciliary dysfunction
￿ Immune dysfunction
￿ Aspirin-exacerbated respiratory disease
￿ Defective mucociliary clearance
￿ Lost ostia patency
￿ Cystic fibrosis.
Management of CRS
Statement 30: When diagnosis of CRS is suggested by
history and objective findings, oral or topical steroids
with or without antibiotics should be used for
management.
Strength of evidence: Moderate
Strength of recommendation: Moderate
Rationale: Once a diagnosis based upon symptoms
and confirmed by imaging or endoscopy is made, contri-
buting or predisposing factors must be identified and
addressed. Unless faced with a complication or severe
illness putting adjacent structures or individual’so v e r a l l
health in jeopardy, initial treatment for individuals with
CRS is medical (Figure 3). CRSsNP is managed with
nasal or oral corticosteroid and oral antibiotics. In
CRSwNP, topical INCS and short courses of oral ster-
oids are the mainstay of management, with simulta-
neous oral antibiotic therapy indicated only in the
presence of symptoms suggesting infection (eg, pain or
recurrent episodes of sinusitis, or when purulence is
documented on rhinoscopy/endoscopy).
Selection of antibiotic therapy differs from ABRS as
bacteriology is different, and tends to be broader spec-
trum. Duration of therapy has not been defined but
trends towards a slightly longer duration than that of
ABRS.
Take Home Points
General management strategies for CRS:
￿ Identify and address contributing or predispos-
ing factors
￿ Oral or topical steroids with or without
antibiotics:
○ Antibiotic therapy should be broader spec-
trum than for ABRS
▪ Empiric therapy should target enteric
Gram-negative organisms, Sa u r e u s ,a n d
anaerobes in addition to the most common
encapsulated organisms associated with an
ABRS (S pneumoniae, H influenzae, M
catarrhalis)
○ Use antibiotics with broad-spectrum cover-
age (eg, amoxicillin-clavulanic acid inhibitors,
fluoroquinolones such as moxifloxacin)
○ Antibiotic therapy duration tends to be
slightly longer than for ABRS.
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initial treatment is medical:
￿ CRSsNP: nasal or oral corticosteroid and oral
antibiotics
￿ CRSwNP: topical INCS and short courses of
oral steroids
○ Simultaneous oral antibiotics indicated only in
the presence of symptoms suggesting infection.
Adapting Therapy to Pathophysiologic Differences
CRS without polyps Bacterial infections are believed to
play an important role in patients with CRSsNP. When
possible, cultures for bacteria and fungi should be
obtained using methods to minimize nasal contamination.
Despite the frequent presence of positive bacterial cul-
tures in CRS, INCS are of benefit and should be pre-
scribed for all patients when diagnosis is confirmed by
objective means. Maximal medical therapy consisting of
antibiotics with or without a short course of oral ster-
oids should be prescribed at the initiation of therapy.
Ancillary measures such as saline irrigation may be of
help. A short course of oral corticosteroid may be
required for more severe symptoms or persistent dis-
ease, according physician assessment.
CRS with polyps INCS remain the mainstay of therapy.
These may be complemented by a short course of oral
steroids in symptomatic subjects. Leukotriene receptor
antagonists may warrant a clinical trial, especially in
patients with ASA sensitivity. In CRSwNP, the presence
of symptoms suggesting infection (eg, pain or recurrent
episodes of sinusitis, or when purulence is documented
on endoscopy) warrants combined therapy with empiric
or culture-directed antibiotics.
Medical Therapy
Anti-infective Agents Antibiotic therapy is considered
an important component in managing exacerbations of
CRS but should be combined with anti-inflammatory
therapy to manage both the inflammatory and infectious
components that contribute to the development and
persistence of CRSsNP.
Although studies of antibiotics show their utility in the
treatment of ABRS, antibiotic use in CRS is based on
extension from first principles. Antibiotic selection must
be judicious; however, guidance as to selection of opti-
mal agent is still unclear and should, for the moment,
be based on logic of bacterial flora. Empiric antibiotic
therapy must be broader than in the treatment of ABRS
because of the greater likelihood of infectious agents
such as Sa u r e u s , Gram-negative enteric organisms, and
anaerobic organisms. Thus, if appropriate bacteriologic
samples cannot be obtained and empiric therapy is
required, as in most clinical situations, consideration
should be given to therapies that target enteric Gram-
negative organisms, S aureus, and anaerobes in addition
to the most common encapsulated organisms associated
with an ABRS (S pneumoniae, H influenzae, M catar-
rhalis). Thus, amoxicillin-clavulanic acid inhibitors or
fluoroquinolones (eg, moxifloxacin) may be prescribed.
There are no high-quality, large-scale, placebo-
controlled studies of antibiotics for CRS. Quality evi-
dence for the use of antibiotics in CRS is thus somewhat
limited. In 2 comparator studies of short-term antibiotic
use for CRS comparing amoxicillin clavulanate to cipro-
floxacin [183] or cefuroxime axetil [184], clinical cure
rates were 51% and 50% for amoxicillin clavulanate and
ciprofloxacin, respectively, and 95% and 88% for amoxi-
cillin clavulanate and cefuroxime. This difference in
outcomes may be a reflection of the criteria used to
diagnose the disease and to determine success.
A number of studies have reported that long-term (eg,
3 months) treatment with low-dose macrolides (eg, roxi-
thromycin, clarithromycin) is effective in improving
symptoms of CRS in adults [185-188]. However, these
series were small, and with the exception of 1 study, did
not include a placebo arm. Additionally, the mechanism
of the effect is not well understood, but may be related
to the ability of macrolides to inhibit the local host
immune response and diminish the virulence of bacteria
[19], rather than via the eradication of bacteria. Despite
the potential interest of this approach to medical ther-
apy, macrolide therapy in its current status has signifi-
cant limitations and is not recommended as standard
therapy in these guidelines. It is of particular interest
that subgroup analysis in at least one of these studies
has shown this therapy to be active only in those indivi-
duals with low serum IgE [188], suggesting that
this effect might be limited to those individuals with
“neutrophilic” chronic sinus disease, as opposed to the
“eosinophilic” disease. However, the optimal patient
phenotype for this type of therapy remains to be better
defined.
The use of topical antibiotics has been studied, with
results ranging from modest benefit to no benefit
[189-191]. However, these studies were performed in
post-ESS settings, where sinus ostia are widely patent
and therapy is capable of directly penetrating the surgi-
cally-widened ostia of the sinuses. Larger, well-designed
studies are needed to clarify the role of this approach to
treat unoperated patients with CRS because penetration
of the antibiotic into the sinus may not be optimal in
the that setting.
Nasal Corticosteroids The benefits of INCS in CRS are
attributed to their anti-inflammatory properties and
effects in relieving nasal congestion and shrinking nasal
polyps. Early studies of INCS in patients with CRSwNP
reported benefit in reducing polyp size and improving
nasal symptoms [192-194]. Recent large-scale rando-
mized trials have confirmed the efficacy of INCS in
patients with CRSwNP [195-199]. One study reported
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tasone furoate significantly reduced polyp grade score
and improved the symptoms of congestion/obstruction,
anterior rhinorrea, postnasal drip, and loss of smell
[197]. Other large, double-blind studies reported signifi-
cant improvements in nasal congestion/obstruction and
reduced polyp size with mometasone compared with
placebo [198,199]. Studies of budesonide have also been
reported to produce significant reductions in polyp size
and improve symptoms compared with placebo
[195,196]. These therapies have been well tolerated.
Inconsistent results have been reported in patients with
CRSsNP. Studies of INCS for CRSsNP are fewer in number
and suffer from a lack of standardized patient definitions
and trial design, making comparisons difficult. In a study
of patients failing antibiotic therapy, a 20-week course of
budesonide nasal spray significantly decreased nasal con-
gestion and discharge and improved sense of smell com-
pared with placebo [200]. However, in a small study of
fluticasone propionate in patients with CRS, no benefit ver-
sus placebo was reported [201]. Larger, well-defined studies
of INCS effectiveness in patients with CRSsNP are needed
[202]. The safety of long-term therapy has nevertheless
been documented. Long-term treatment with INCS may
cause minor epistaxis, but is not associated with adverse
structural changes or thinning of the epithelium [203].
Despite the absence of stro n gs u p p o r t i n ge v i d e n c e ,
given the pronounced inflammatory component in both
CRSwNP and CRSsNP, it is the consideration of the
group that treatment with INCS is an important part of
t h em a n a g e m e n to fC R Sa n ds h o u l db ei n c l u d e di na l l
patients with CRS with or without nasal polyps.
For severe polypoid disease not responding to INCS,
studies have reported that a short course (2 weeks) of
prednisone is effective to reduce polyp size, followed by
long-term INCS to maintain the benefit [204-206].
Short-course systemic steroids have also been of benefit
prior to endoscopic surgery. The minimal effective dose
of systemic corticosteroids should be used to minimize
potentially serious side effects [19].
Take Home Points
CRS without polyps:
￿ INCS should be prescribed for all patients
○ Benefits include:
▪ Addressing inflammatory component of
CRS
￿ Antibiotics with or without a short course of
oral steroids should be prescribed at the initia-
tion of therapy
￿ Ancillary measures such as saline irrigation
may be of help
￿ A short course of oral corticosteroid may be
required for more severe symptoms or persistent
disease.
CRS with polyps:
￿ INCS are the mainstay of therapy
○ Benefits include:
▪ Addressing inflammatory component of
CRS
▪ Relieving nasal congestion
▪ Shrinking nasal polyps
￿ A short course of oral steroids may be pre-
scribed in symptomatic subjects
○ 2-week course of prednisone may reduce
polyp size in patients unresponsive to INCS
￿ Leukotriene receptor antagonists may warrant a
trial, especially in patients with ASA sensitivity
￿ Combined therapy with empiric or culture-
directed antibiotics are indicated in the presence
of symptoms suggesting infection (eg, pain or
recurrent episodes of sinusitis, or when puru-
lence is documented on endoscopy).
Adjunct Therapy Statement 31: Many adjunct thera-
pies commonly used in CRS have limited evidence to
support their use. Saline irrigation is an approach that
has consistent evidence of benefiting symptoms of CRS.
Strength of evidence: Moderate
Strength of recommendation: Moderate
Statement 32. Use of mucolytics is an approach that
may benefit symptoms of CRS.
Strength of evidence: Option
Strength of recommendation: Moderate
Statement 33. Use of antihistamines is an approach
that may benefit symptoms of CRS.
Strength of evidence: Option
Strength of recommendation: Weak
Statement 34. Use of decongestants is an approach
that may benefit symptoms of CRS.
Strength of evidence: Option
Strength of recommendation: Weak
Statement 35. Use of leukotriene modifiers is an
approach that may benefit symptoms of CRS.
Strength of evidence: Weak
Strength of recommendation: Weak
Rationale
Saline Buffered saline irrigation facilitates mechanical
removal of mucus, decreases crusting, and is thought to
facilitate removal of infective agents and inflammatory
mediators, and increase ciliary beat frequency [207].
Thus, it is a valuable adjunctive therapy that is used in a
variety of sino-nasal conditions ranging from CRS and
allergic rhinitis to post-operative care. Although well-
designed studies in CRS are lacking, a recent Cochrane
review reported that nasal saline irrigation was effective
in relieving symptoms of CRS [207].
Mucolytics Guaifenesin has been demonstrated to be an
effective expectorant and theoretically should benefit
removal of tenacious mucus from sinuses. A small study
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sinonasal disease reported less congestion and thinner
postnasal drainage with guaifenesin versus placebo
[116]. However, no clinical trials have evaluated the use
of mucolytic agents in patients with CRS, so its use
remains empiric. Recommended doses of mucolytics are
high (eg, guaifenesin 2400 mg/d) [208] and are not
available in these concentrations in Canada.
Antihistamines No clinical trials have demonstrated
that antihistamines improve symptoms in patients with
CRS, but antihistamines have reported benefit in
patients with documented inhalant allergies [209].
Decongestants Due to the concern of aggravating CRS
due to development of rhinitis medicamentosa from
long-term use of topical decongestants [210], prolonged
use of these agents should be avoided. Oral deconge-
stants have not been adequately evaluated in CRS but
concerns remain regarding systemic effects with long-
term use. They may be of benefit during short-term
exacerbations from presumed viral episodes.
Leukotriene modifiers Small studies of the leukotriene
modifiers, zileuton and zafirlukast, have supported a
potential role for these agents in alleviating symptoms
in patients with sinus symptoms and nasal polyps
[211,212]. Montelukast has also reported symptomatic
improvement in patients with asthma and nasal polypo-
sis [213], as well as preventing recurrence of polyps in
patients with aspirin sensitivity [214,215]. However, lar-
ger randomized studies are needed to explore patient
subtypes likely to benefit from this approach. Leuko-
triene modifiers are not currently recommended for the
treatment of CRS.
Anti-mycotic agents Although antimycotic agents have
been used in the treatment of invasive fungal rhinosinu-
sitis and allergic fungal rhinosinusitis, they have not
shown efficacy in treating patients with CRS with or
without nasal polyps [216-219]. A recent large, rando-
mized, placebo-controlled trial in patients with CRSsNP
reported no difference in symptom improvement
between intranasal amphotericin B and nasal saline irri-
gation [220].
Anti-inflammatory agents COX-1 and COX-2 inhibi-
tors have not been demonstrated to be effective in CRS
aside from modifying associated pain. Macrolides have
been shown to have anti-inflammatory properties in
other respiratory conditions and limited data suggests
these may be beneficial in CRS. Further studies are
needed.
Immunomodulatory agents Minimal data exists for use
of agents such as interferon gamma [221]. At present
there is no data to support the use of any specific cyto-
kine or anti-cytokine in CRS.
Aspirin desensitization In individuals with ASA sensi-
tivity, treatment for aspirin-exacerbated respiratory
disease (AERD) has included aspirin desensitization.
Studies have demonstrated efficacy of a 3-day desensi-
tization protocol followed by daily high dose ASA
(usually 650 mg bid) in treating severe nasal polyposis
in patients with AERD [222]. Some improvements have
also been demonstrated with anti-leukotriene therapy
in patients with AERD [223], but more studies are
needed. Of note is that compliance to therapy is essen-
tial, as therapy must be reinitiated if more than 2 doses
are missed. There are very few centers experienced in
this therapy and none currently perform this in
Canada, and thus this therapy is not recommended at
this juncture.
Failure of response
Statement 36: Failure of response should lead to con-
sideration of other possible contributing diagnoses such
as migraine or temporomandibular joint dysfunction
(TMD)
Strength of evidence: Option
Strength of recommendation: Moderate
Rationale: Alternate diagnoses that can be considered
and may need to be distinguished from CRS include:
allergic rhinitis, nonallergic rhinitis, vasomotor rhinitis,
allergic fungal rhinosinusitis, invasive fungal rhinosinus-
tis, nasal septal deformation, atypical facial pain,
migraine or other headache diagnosis, TMD, and tri-
geminal neuralgia [9].
Take Home Points
Adjunct therapies may benefit symptoms of CRS:
￿ Approaches with consistent evidence of bene-
fiting symptoms:
○ Saline irrigation
￿ Approaches with limited evidence of benefiting
symptoms:
○ Mucolytics
○ Antihistamines
○ Leukotriene modifiers.
Failure of response should prompt consideration of
other possible/contributing diagnoses:
￿ Allergic fungal rhinosinusitis
￿ Allergic rhinitis
￿ Atypical facial pain
￿ Invasive fungal rhinosinustis
￿ Migraine or other headache diagnosis
￿ Nasal septal deformation
￿ Nonallergic rhinitis
￿ Temporomandibular joint dysfunction (TMD)
￿ Trigeminal neuralgia
￿ Vasomotor rhinitis.
Surgery
Statement 37: Surgery is beneficial and indicated for
individuals failing medical treatment.
Strength of evidence: Weak
Strength of recommendation: Moderate
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respond to medical therapy. Efficacy of surgery has not
been assessed as extensively as has that of medical ther-
apy but response rates of 50% to 90% have been docu-
mented in prospective series. Studies of the impact of
ESS on patient quality of life have consistently reported
significant improvement after the surgery [224,225].
Compelling clinical trial evidence for the efficacy of
ESS remains scanty [226]. Trial design is possibly an
issue. ESS remains a vital tool in the physician’sa r m a -
mentarium for clearing diseased mucosa, relieving
obstruction, and restoring ventilation, but it should be
reserved for those individuals having failed maximal
medical therapy. The definition of maximal medical
therapy remains to be standardized. Theoretical risks of
surgery need to be counterbalanced with the equally
important risks of prolonged courses of antibiotics and
oral steroid therapy.
Among the CRS cases that prove difficult to cure uti-
lizing medical management alone, a majority of patients
have a combination of pathophysiological and anatomi-
cal factors predisposing to the chronic inflammation
and bacterial presence [227]. Most of these patients will
need to be referred to an otolaryngologist for assess-
ment of disease and for maximal medical management,
if not already administered. A percentage of these
patients will reverse their disease without surgical inter-
vention, however the majority will require appropriate
medical management pre- and post-surgery for a suc-
cessful outcome.
In CRS, the goal of surgery is to re-establish sinus
drainage by removing excess tissue responsible for
obstruction and bony areas in narrow areas. The extent
of surgery is guided by the degree of sinus involvement.
Minimally invasive ESS techniques are now used and
often performed on a day surgery basis. Meta-analyses
of studies of ESS for adult CRS have reported improve-
ment in symptoms and quality of life [228], and fatigue
[229] but these same analyses also note the lack of high-
grade evidence.
Statement 38: Continued use of medical therapy post-
surgery is key to success and is required for all patients.
Evidence remains limited.
Strength of evidence: Moderate
Strength of recommendation: Moderate
Rationale: Early postoperative care varies between
individual surgeons but usually involves antibiotics, topi-
c a lo ro r a lc o r t i c o s t e r o i d s , and saline irrigation. Post-
operative pain and dysfunction should be minimal and
patients who develop severe symptoms of pain, tempera-
ture, or new-onset colored secretions should be referred
rapidly back to the operating surgeon.
INCS after ESS has shown variable results. One study
of patients post-ESS reported that a 3-week course
with budesonide improved symptom scores and
decreased inflammatory mediators in allergic patients
with CRS [230]. In a 5-year study of patients following
ESS, use of fluticasone propionate nasal spray twice
daily significantly improved symptom and polyp scores
[231]. However, another study reported that flutica-
sone- and placebo-treated patients had similar rates of
polyp recurrence and CRS during the first year after
ESS [232]. In a study of CRSwNP and CRSsNP patients
post-ESS, a 6-month course of mometasone furoate
improved an endoscopic combination score for inflam-
mation, edema, and polyps, compared with placebo,
particularly in patients with CRSwNP. Improvement in
other endoscopic parameters did not reach statistical
significance. Study authors reported that mometasone
furoate improved wound healing post ESS [233].
Another study of mometasone furoate examined time
to polyp relapse post ESS. In this study, patients
receiving mometasone furoate 200 mcg twice daily had
significantly longer time to relapse compared with pla-
cebo [234].
Systemic steroids have been used preoperatively, with
benefit being reported postoperatively [235]. Nasal saline
irrigation is recommended [135], although robust clini-
cal trial data is lacking. Because CRS has been reported
to recur in patients with highp e r i p h e r a le o s i n o p h i l
counts, asthma, or mucosal eosinophil CRS, these
patients should be followed closely [236], and may
require long-term treatment with anti-inflammatory
agents (steroids).
Take Home Points
Endoscopic Sinus Surgery (ESS)
￿ Indicated for patients who fail maximal medical
therapy
￿ Goal:
○ Clear diseased mucosa
○ Relieve obstruction
○ Restore ventilation
￿ Provide specialist referral
￿ Provide post-surgical follow-up
○ Immediate postoperative care involves anti-
biotics, topical/oral corticosteroids, and saline
irrigation
○ Monitor patient for severe symptoms of
pain, fever, or new-onset colored
secretions
▪ Immediately refer to operating surgeon
○ Continued care includes nasal saline irriga-
tion and INCS, with limited evidence
○ CRS patients with high peripheral eosino-
phil counts, asthma, or mucosal eosinophil
C R Ss h o u l db ef o l l o w e dc l o s e l y ,a n dm a y
require long-term treatment with anti-inflam-
matory agents (steroids).
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Statement 39 Part A: Patients should be referred by
their primary care physician when failing 1 or more
courses of maximal medical therapy or for more than 3
sinus infections per year.
Strength of evidence: Weak
Strength of recommendation: Moderate
Rationale Part A: Symptoms not responding to initial
therapy require confirmation of diagnosis by endoscopy
or CT scan. Endoscopic culture may help direct therapy.
Statement 39 Part B: Urgent consultation with the
otolaryngologist should be obtained for individuals with
severe symptoms of pain or swelling of the sinus areas
or in immunosuppressed patients.
Strength of evidence: Weak
Strength of recommendation: Strong
Rationale Part B: Severe symptoms can be suggestive
of incipient complications and may require urgent ima-
ging, antibiotic therapy, and possible surgical drainage
to prevent development of complications.
No improvement in symptoms after 4 weeks of maxi-
mal medical management (allergen avoidance measures,
topical steroids, nasal irrigation, systemic antibiotics) or
the presence of suspected orbital or neurological com-
plications (as noted above) warrant referral to an
otolaryngologist.
Allergy Testing
Statement 40: Allergy testing is recommended for indi-
viduals with CRS as potential allergens may be in their
environment.
Strength of evidence: Option
Strength of recommendation: Moderate
Rationale: The role of allergy in CRS is not well
understood. However, allergy has been reported to be
present in 60% of patients with CRS refractory to medi-
cal treatment [129]. In 1 study, nearly half of patients
with CRS and previous sinus surgery reported that
immunotherapy was needed to address their symptoms
[237]. Thus, allergy testing is useful to identify patients
with allergic components of rhinosinusitis that might
respond to allergy treatment (eg, avoiding environmental
triggers, or taking appropriate pharmacotherapy or
immunotherapy).
Immune Function
Statement 41: Assessment of immune function is not
required in uncomplicated cases
Strength of evidence: Weak
Strength of recommendation: Strong
Rationale: Immune testing is not indicated in uncom-
plicated cases of CRS. However, it may be appropriate
for patients with resistant CRS. Studies have reported
that 22% to 55% of patients with refractory CRS had
abnormal immunologic test results, most commonly IgG
deficiency [238,239].
Take Home Points
Specialist referral:
￿ Referral to a specialist is warranted when a
patient
○ Fails ≥ 1 course of maximal medical
therapy or
○ Has > 3 sinus infections/year
￿ URGENT consultation w/otolaryngologist is
required when a patient:
○ Has severe symptoms of pain/swelling of
the sinus areas, or
○ Is immunosuppressed.
Testing:
￿ Allergy
○ Recommended to identify allergic compo-
nents that might respond to allergy treatment
(eg, avoiding environmental triggers, or tak-
ing appropriate pharmacotherapy or
immunotherapy)
￿ Immune function
○ Not required in uncomplicated cases
○ May be appropriate for patients with resis-
tant CRS.
Prevention
Statement 42: Prevention measures should be discussed
with patients.
Strength of evidence: Weak
Strength of recommendation: Strong
Rationale: Avoidance of predisposing allergic trigger-
ing factors is warranted despite lack of prospective stu-
dies in CRS. Both home and work environments should
be assessed.
The focus of prevention in patients with CRS is to
avoid acute exacerbations. Patients should be instructed
to use proper hand-washing hygiene to minimize viral
rhinosinusitis [127], avoid smoking [240], and perform
saline nasal irrigation [207].
Take Home Points
The goal of prevention is to avoid acute
exacerbations:
￿ Avoid predisposing allergic triggering factors
○ Assess both home and work environments
for triggering factors
￿ Use proper hand-washing hygiene
￿ Avoid smoking
￿ Perform saline nasal irrigation.
Summary
Despite national and international efforts to develop
comprehensive guidelines, high-quality evidence for
many rhinosinusitis recommendations remains limited
or nonexistent. Although our understanding of the
pathophysiology of acute rhinosinusitis (ARS) and
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during the past decade, our understanding of the under-
lying mechanisms remains limited. This incomplete evi-
dence base translates into continued difficulty with
classifying the various forms of rhinosinusitis, selecting
among available therapies, and developing new thera-
peutic options. Selecting appropriate therapy thus
remains a challenge for both ARS and CRS. Professional
experience and expert opinions are required to develop
recommendations because of the absence of well-
designed prospective clinical trials of therapeutic
options. Future research must improve our understand-
ing of rhinosinusitis and provide a strong evidence base
for therapeutic recommendations.
Much remains to be settled in ARS to improve diag-
nostic criteria and direct treatment, including a better
understanding of the timelines of pathophysiological
changes during rhinovirus infection, host factors asso-
ciated with the transition to bacterial infection, and the
role of mucosal immunity, as well as severity of sympto-
matology and predictors of non-resolution/complica-
t i o n s .T h er o l eo fa n t i b i o t i ct h e r a p yi nA R Sh a sb e e n
under scrutiny, which will likely lead to changes in clini-
cal trial design. Improving objective methods of identify-
ing ARS cases that warrant therapy will permit more
rigorous and meaningful patient selection. Randomized,
placebo-controlled studies should test the effectiveness
of antibiotics and other treatments using direct mea-
sures of bacterial presence and viability at the beginning
and end of therapy, rather than relying on symptomatic
improvement. Trial designs that include identification of
predictors of positive response to therapy would facili-
tate the development of recommendations.
Many aspects of CRS remain controversial and a bet-
ter understanding of the pathophysiology, definitions,
and role of causative factors will improve treatment
approaches. As more information about CRS subtypes
and novel therapies are discovered, large-scale, prospec-
tive, placebo-controlled trials of therapies will need to
be repeated in the context of the various subtypes.
Delivery methods that improve coverage of the nasal
passages and/or penetration of the sinus cavities are
needed. As results from studies of medical and surgical
approaches increase, attempts should be made to iden-
tify the optimal therapy according to subtypes of disease
and time point in the disease evolution. Post-operative
medical management needs to be better recognized.
Because there is a large number of patients with persis-
tent signs and symptoms of the disease despite medical
and surgical intervention, management guidelines speci-
fic to this group of patients should be developed.
The past 2 decades have seen a rapid increase in our
knowledge of the pathogenesis, diagnosis, and manage-
ment of ARS and CRS. It is hoped that over the next
decade, study findings will expand and build upon the
current foundation to bring scientific credibility and
improved outcomes to our field.
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